

1 **Title:** The microbiome diversifies *N*-acyl lipid pools - including short-chain fatty acid-
2 derived compounds.

3

4 **Authors:**

5 Helena Mannocho-Russo¹, Vincent Charron-Lamoureux¹, Martijn van Faassen^{1,2},
6 Santosh Lamichhane^{1,3}, Wilhan D. Gonçalves Nunes¹, Victoria Deleray¹, Abubaker
7 Patan¹, Kyle Vittali¹, Prajit Rajkumar¹, Yasin El Abiead¹, Haoqi Nina Zhao¹, Paulo
8 Wender Portal Gomes¹, Ipsita Mohanty¹, Carlynda Lee¹, Aidan Sund¹, Meera Sharma¹,
9 Yuanhao Liu¹, David Pattynama¹, Gregory T. Walker⁴, Grant J. Norton⁴, Lora Khatib^{5,6},
10 Mohammadsobhan S. Andalibi^{5,7,8,9}, Crystal X. Wang^{8,9}, Ronald J. Ellis^{7,9}, David J.
11 Moore^{8,9}, Jennifer E. Iudicello^{8,9}, Donald Franklin, Jr.^{8,9}, Scott Letendre^{9,10}, Loryn
12 Chin^{5,11,12}, Corinn Walker⁵, Simone Renwick^{5,13}, Jasmine Zemlin^{1,12}, Michael J. Meehan¹,
13 Xinyang Song^{14,15}, Dennis Kasper¹⁴, Zachary Burcham¹⁶, Jane J. Kim^{17,18}, Sejal
14 Kadakia¹⁹, Manuela Raffatellu^{4,12,20}, Lars Bode^{5,13}, Karsten Zengler^{5,11,12}, Mingxun
15 Wang²¹, Dionicio Siegel¹, Rob Knight^{5,12,22,23,24}, Pieter C. Dorrestein^{1,12,25,26}

16

17 **Author affiliations:**

18 ¹ Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San
19 Diego, La Jolla, CA, USA

20 ² Department of Laboratory Medicine, University of Groningen, University Medical Center
21 Groningen, 9713 GZ Groningen, the Netherlands

22 ³ Turku Bioscience Center, University of Turku and Åbo Akademi University, 20520 Turku,
23 Finland

24 ⁴ Division of Host-Microbe Systems & Therapeutics, Department of Pediatrics, University
25 of California San Diego, La Jolla, CA 92093, USA

26 ⁵ Department of Pediatrics, University of California San Diego, La Jolla, California, USA

27 ⁶ Neurosciences Graduate Program, University of California San Diego, La Jolla,
28 California, USA

29 ⁷ Department of Neurosciences, University of California San Diego, San Diego, CA
30 92093, USA

31 ⁸ Department of Psychiatry, University of California San Diego, San Diego, CA 92093,
32 USA

33 ⁹ HIV Neurobehavioral Research Program, University of California San Diego, San Diego,
34 CA 92093, USA

35 ¹⁰ Department of Medicine, University of California San Diego, La Jolla, CA, USA

36 ¹¹ Department of Bioengineering, University of California, San Diego, La Jolla, CA, 92093,
37 USA

38 ¹² Center for Microbiome Innovation, University of California, San Diego, La Jolla, CA,
39 92093, USA

40 ¹³ Larsson-Rosenquist Foundation Mother-Milk-Infant Center of Research Excellence
41 (MOMI CORE) and the Human Milk Institute (HMI), University of California San Diego, La
42 Jolla, CA, 92093, USA

43 ¹⁴ Department of Immunology, Harvard Medical School, Boston, MA 02115, USA

44 ¹⁵ Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell
45 Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences,
46 University of Chinese Academy of Sciences, Shanghai, 200031, China

47 ¹⁶ Department of Microbiology, University of Tennessee, Knoxville, Tennessee, USA

48 ¹⁷ Department of Pediatrics, Division of Pediatric Endocrinology, University of California
49 San Diego, California, USA

50 ¹⁸ Rady Children's Hospital San Diego, San Diego, California, USA

51 ¹⁹ Division of Pediatric Endocrinology, Children's Hospital of Orange County, Orange, CA,
52 USA

53 ²⁰ Chiba University-UC San Diego Center for Mucosal Immunology, Allergy, and
54 Vaccines, La Jolla, California 92093, USA

55 ²¹ Department of Computer Science and Engineering, University of California Riverside,
56 Riverside, CA, USA

57 ²² Department of Computer Science and Engineering, University of California, San Diego,
58 La Jolla, CA, USA

59 ²³ Halicioğlu Data Science Institute, University of California, San Diego, La Jolla, CA, USA

60 ²⁴ Shu Chien-Gene Lay Department of Bioengineering, University of California, San
61 Diego, La Jolla, CA, USA

62 ²⁵ Collaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and
63 Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA

64 ²⁶ Department of Pharmacology, University of California San Diego, La Jolla, CA, 92093,
65 USA

66

67 *Correspondence: pdorrestein@health.ucsd.edu

68

69 **Abstract:** *N*-acyl lipids are important mediators of several biological processes including
70 immune function and stress response. To enhance the detection of *N*-acyl lipids with
71 untargeted mass spectrometry-based metabolomics, we created a reference spectral
72 library retrieving *N*-acyl lipid patterns from 2,700 public datasets, identifying 851 *N*-acyl
73 lipids that were detected 356,542 times. 777 are not documented in lipid structural
74 databases, with 18% of these derived from short-chain fatty acids and found in the
75 digestive tract and other organs. Their levels varied with diet, microbial colonization, and
76 in people living with diabetes. We used the library to link microbial *N*-acyl lipids, including
77 histamine and polyamine conjugates, to HIV status and cognitive impairment. This
78 resource will enhance the annotation of these compounds in future studies to further the

79 understanding of their roles in health and disease and highlight the value of large-scale
80 untargeted metabolomics data for metabolite discovery.

81
82 **Introduction:** *N*-acyl lipids are signaling molecules consisting of two components: a fatty
83 acid and an amine group, linked by an amide bond (**Figure 1A**). The previously described
84 *N*-acyl lipids are involved in crucial biological functions, including immune homeostasis,
85 building of fat mass levels, regulation of energy expenditure related to obesity, and they
86 regulate other processes such as pain, memory, and insulin levels.^{1–6} Representative
87 examples include *N*-oleoylethanolamine, which controls food intake, *N*-acyl taurine, which
88 improves insulin sensitivity, and *N*-arachidonoyl 3-OH- γ -aminobutyric acid, which
89 regulates calcium-dependent voltage channel function.^{7,8} Other *N*-acyl lipids, such as *N*-
90 acetyl cysteine and N^{α} -lauroyl-L-arginate, are used as an FDA-approved drug and a food
91 ingredient, respectively. *N*-acetyl cysteine has antioxidant and anti-inflammatory
92 properties and is used to block acetaminophen poisoning, as well as to break up mucus
93 in respiratory diseases.⁹ On the other hand, N^{α} -lauroyl-L-arginate acts as an antimicrobial
94 agent, inhibiting bacteria, yeasts, and molds in food products.⁸ These are only a few
95 examples of *N*-acyl lipids, but these molecules are chemically very diverse. LIPID MAPS,
96 one of the most comprehensive lipid structural databases,¹⁰ currently catalogs close to
97 400 *N*-acyl lipids comprising 76 different headgroups derived from primary amines or
98 amino acids (**Supplementary Figure 1A,B**).

99
100 Known *N*-acyl lipids can be identified through targeted mass spectrometry (MS)
101 approaches,^{11–14} but both known and novel *N*-acyl lipids often go unreported in untargeted
102 metabolomics data due to the lack of reference MS/MS spectra. We hypothesized that
103 many *N*-acyl lipids relevant to biology exist within publicly available LC-MS/MS untargeted
104 metabolomics data but remain unannotated due to the absence of relevant spectral
105 libraries. Building on these efforts, we developed a novel strategy to create a reusable *N*-
106 acyl lipid resource to reinterpret existing data from the untargeted metabolomics
107 repository, GNPS/MassIVE. In this way, the biological function of *N*-acyl lipids in different
108 contexts can be elucidated and we can ensure that future untargeted metabolomics
109 studies will not overlook these important metabolites. Our approach leverages the reverse
110 metabolomics strategy, where MS/MS spectra can serve as proxies for metabolites,
111 which are then matched across public studies to contextualize their biological
112 relevance.^{14–22}


113
114 **Results:**

115 **Detection of *N*-acyl lipids in public data.** To uncover the presence of *N*-acyl lipids and
116 improve their detection in existing public untargeted metabolomics data, we developed
117 the Mass Spec Query Language (MassQL) queries²⁰ for 8,256 different *N*-acyl lipids with
118 64 amines and amino acids as headgroups (**Supplementary Table 1, Supplementary**

119 **Figure 1C,D**). We applied these queries to filter MS/MS data from the GNPS-based
120 untargeted metabolomics data (2,706 datasets as of January 2024, and includes ~1.2
121 billion MS/MS spectra). The fragmentation-based queries were confined to 2- to 30-
122 carbon fatty acids with up to four unsaturations. This range was selected because these
123 fatty acids fragment predictably due to the limited presence of internal fragments, making
124 it more straightforward to develop specific queries for which we could keep low false
125 discovery rates (**Supplementary Methods, Supplementary Figure 1C,D**). Of the 64
126 headgroups we created queries for, 41 have not been documented in comprehensive
127 curated lipid structure databases such as LIPID MAPS,¹⁰ LipidBANK,²³ or SwissLipids,²⁴
128 making their existence and/or prevalence in biology, including human biology, unclear
129 (**Supplementary Figure 1A,B**).²⁵

130
131 Of the 64 amines and amino acid headgroups, we found that 46 were linked with
132 2- to 30-carbon fatty acids in public data (**Figure 1B**). These represented 851 compounds
133 of the theoretically 8,256 possible candidates from our initial MassQL searches (**Figure**
134 **1B, Supplementary Table S1**). A reusable MS/MS spectral library was created as a
135 resource to enable other researchers to investigate *N*-acyl lipids in mass spectrometry-
136 based metabolomics studies in the future. 552 spectra were confirmed to match their
137 MS/MS using reference MS/MS of standards created using combinatorial organic
138 synthesis^{14,26} (**Figure 1B**). These represent level 2 or 3 annotations according to both the
139 2007 Metabolomics Standards Initiative and the 2014 Schymanski rules for untargeted
140 metabolomics annotation.^{27,28} In the absence of physical samples, this is the highest level
141 of annotation currently possible for annotating MS/MS data in public data.

142
143 The most frequently detected lipid conjugate was acetylation (C2).²⁵ While
144 saturated carbons were the most common, an unexpected finding was the prevalence of
145 both saturated and unsaturated C3-C6 short-chain fatty acid-derived *N*-acyl lipids, which
146 are rarely reported in the lipid structural databases (**Supplementary Figure 1B**).^{10,24,25}
147 Irrespective of fatty acid length, the saturated fatty acid containing *N*-acyl lipids were
148 detected most frequently - followed by one, two, three, and four unsaturations. The most
149 common fatty acids linked to *N*-acyl lipids were C18:1 and C16:1 for one double bond,
150 and C18:2, C18:3, and C20:4 for two, three, and four unsaturations, respectively. Very
151 long chain-linked *N*-acyl lipids are less frequently observed. Even-carbon lipid chains
152 accounted for 87% of matches (**Supplementary Table S1**). Tyramine had the highest
153 number of different fatty acid attachments, followed by leucine, phenylalanine, and
154 tryptamine. Glutamine was associated with rare C8-C18 lipids, while tyramine,
155 tryptamine, dopamine, and serotonin had rare C20-C30 lipid attachments (**Figure 1B**).
156




157
 158 **Figure 1. Repository-scale analysis of *N*-Acyl lipids in public mass spectrometry data and**
 159 **distribution among different tissues or biofluids. (A) *N*-acyl lipid definitions and isomers:** this panel
 160 explains *N*-acyl lipids using a C5:1 tail example. A C5:1 lipid consists of a five-carbon fatty acid with one
 161 double bond. The image illustrates the possible isomers for this structure that can yield the same MS/MS
 162 spectrum. **(B) Heatmap of *N*-acyl lipids:** the heatmap shows 851 *N*-acyl lipids identified from public MS data
 163 in the MassIVE/GNPS repository using MassQL queries.²⁰ Validation of the data was performed using
 164 cosine similarity (see **Supplementary Figure 1E**). Compounds found in microbial cultures are marked with
 165 purple squares, those matched with synthetic standards are indicated by black stars, and those confirmed
 166 by retention time with biological samples are shown with red stars. **(C) and (D) Heatmaps showing**

167 distribution in tissues and biofluids: number of matches of different fatty acid chain lengths in tissues and
168 biofluids with metadata available in ReDU¹⁹ for **(C)** rodent and **(D)** human-related public datasets. All
169 heatmaps are shown as log values of the matches obtained from the repository, regardless of the
170 headgroup. Icons were obtained from Bioicons.com.

171
172 With the *N*-acyl lipids MS/MS spectra obtained using MassQL,²⁰ we performed a
173 MASST^{18,29} search against the entire GNPS repository to link the retrieved spectra to their
174 biological associations. We obtained 356,542 MS/MS spectra from 61,833 files across
175 950 datasets, highlighting the widespread detection of *N*-acyl lipids in untargeted
176 metabolomics studies. As little is known about the biology associated with *N*-acyl lipids,
177 we leveraged the reverse metabolomics strategy¹⁴ to understand their presence in
178 rodents, and humans, and their distribution across organs, biofluids, and other sources
179 such as food, plants, or microbial cultures. By considering additional metadata curated
180 with controlled vocabularies using the ReDU¹⁹ infrastructure in GNPS²¹, we could
181 categorize *N*-acyl lipids detected in tissues and biofluids from humans and rodents,
182 representing 435 and 259 *N*-acyl lipids, respectively. The tissue and biofluid distribution
183 in rodents and humans, including the number of MS/MS spectra, unique *N*-acyl lipids
184 headgroups, and different acyl chain lengths are depicted in **Supplementary Figure**
185 **2A,B**. The most frequently observed chain lengths in both humans and rodents were C2,
186 C12, C16, and C18, as illustrated in **Figures 1C** and **1D**. Odd-chain lipid chains were also
187 detected in both human and rodent datasets with C3:0 (propionate) and C5:0 (valerate),
188 both classified as short-chain fatty acid-derived molecules, being the most frequently
189 detected among them. In rodents, C3:0 was primarily observed in the colon, caecum,
190 esophagus, and feces, while C5:0 was mostly found in feces and blood. In humans, C3:0
191 was detected in saliva, the vagina, and feces, while C5:0 was present in the oral cavity,
192 urine, blood, and cerebrospinal fluid, in addition to feces. The most common head groups
193 identified in both humans and rodents were phenylalanine, spermidine, (iso)leucine, and
194 alanine/sarcosine (**Supplementary Figure 2C,D**). The data suggests that *N*-acyl lipids
195 occupy specific body niches. Aspartic acid, aminoadipic acid, and spermidine lipids were
196 primarily found in the brain and rarely in other body locations. Spermidine-conjugated
197 lipids appeared frequently in saliva, while glutamine *N*-acyl lipids were more common in
198 blood, skin, and urine. Tyrosine-conjugated lipids, however, were almost exclusively
199 detected in human milk.

200
201 Out of the 851 *N*-acyl lipids, 347 were detected in data from microbial cultures
202 using microbeMASST¹⁵ (**Figure 1B**, **Figure 2A,B**, **Supplementary Table S1**). The most
203 commonly observed *N*-acyl lipids in these microbial monocultures had phenylalanine,
204 leucine, and tyrosine as headgroups (**Figure 2A**), with an overall predominance of even-
205 chain lengths (**Figure 2B**). Additionally, 167 and 243 of the 851 candidate *N*-acyl lipids
206 were detected in plant and food datasets, respectively (**Figure 2C**, **Supplementary Table**
207 **S2**). This distribution stratified by lipid chain length revealed that short, medium, and long-

208 chain conjugates are predominantly detected in human, microbial, and rodent-related
 209 datasets, while very long-chain *N*-acyl lipids are observed almost exclusively in plants
 210 and foods (**Figure 2D, Supplementary Figure 3A-D**). These differences in *N*-acyl lipids
 211 found in food and plant data compared to microbial cultures, rodent, and human datasets
 212 suggest they may be consumed through diet but also produced by the microbiota.
 213



214
 215 **Figure 2. Evidence of microbial origins of *N*-acyl lipids.** Heatmaps depict the distribution of different
 216 headgroups (**A**) and tails (**B**) across various microbial classes, with barplots showing the total counts for
 217 each class in microbeMASST.¹⁵ The Y-axis was taxonomically ordered according to the NCBI Taxonomy
 218 ID, while the X-axis was clustered using the Braycurtis metric for the headgroups, or in ascending order (in
 219 number of carbons and unsaturations) for the tails. **C**) UpSet plot of *N*-acyl lipid distribution: This plot

220 highlights the distribution of *N*-acyl lipids across different datasets, including human-related, rodent-related,
221 microbial monocultures, plant-, and food-associated data. **D)** Distribution of *N*-acyl lipid chain lengths: This
222 summary shows the prevalence of short, medium, long, and very long chain *N*-acyl lipids in public data.
223 Note that the exact location and cis/trans configurations of double bonds cannot be determined from the
224 current queries, which are annotated at the molecular family level according to the Metabolomics Standards
225 Initiative.²⁷ **E** and **F)** Volcano plots of mouse fecal pellets from a dataset publicly available (GNPS/MassIVE:
226 [MSV000080918](#))³⁰ showing *N*-acyl lipids up-regulated and down-regulated upon different diets (**E**) and
227 antibiotic treatment (**F**). The significant thresholds are marked by dotted lines in the volcano plot ($p < 0.05$
228 and $\log_2(\text{FC}) > 2$ or < -2). Differential compounds between the groups were evaluated using the non-
229 parametric two-sided Mann-Whitney U test, and p-values were corrected for multiple comparisons using
230 the Benjamini-Hochberg correction. Icons were obtained from Bioicons.com.

231
232 This hypothesis was further evaluated by the analysis of a public dataset of small
233 intestine and colon samples, where germ-free (GF) mice were colonized with a
234 conventional gut microbiota (Specific Pathogen Free, SPF), or monocolonized with
235 Segmented Filamentous Bacteria (SFB), or other gut commensal strains.^{31,32} In addition,
236 we conducted another culturing experiment with human-derived microbiota to enable
237 MS/MS and retention time matching. Both datasets revealed a mixture of both
238 consumption and production of *N*-acyl lipids, providing additional evidence that the
239 microbiota regulates *N*-acyl lipid levels. These results are also consistent with a recent
240 report of a *Faecalibacterium prausnitzii* hydrolase that has both amide hydrolase and *N*-
241 acylation function.³³

242
243 The *N*-acyl lipid profile in the small intestine and colon differed in mice colonized
244 with conventional microbiota (SPF) or monocolonized with SFB compared to GF mice. In
245 addition, the reanalysis of other monocolonized mouse samples revealed that short-chain
246 fatty acids generally increased, while those conjugated with longer chains decreased
247 compared to GF mice, with cases of microbe-specificity, supporting the hypothesis that
248 microbes may be involved in *N*-acyl lipids production (**Supplementary Figure 3E**).
249 Culturing 71 commensal bacteria from the human gut also revealed their ability to make
250 *N*-acyl lipids and provided additional support for this hypothesis.³⁴ Since the vast majority
251 of these microbes are not yet part of microbeMASST, this approach provided both
252 orthogonal evidence and experimental validation of microbial-linked *N*-acyl lipids. We
253 obtained 50 MS/MS matches to the *N*-acyl lipids resource, with 38 corresponding to *N*-
254 acyl lipids conjugated to short-chain fatty acids (**Supplementary Figure 3F**,
255 **Supplementary Figure 4A,B**). We observed that short-chain *N*-acyl lipids increased
256 compared to the culture media, while longer chains (C8-C12) generally decreased, except
257 for ornithine-C17:1, and leucine and methionine-C9:4, suggesting that the microbiota is
258 able to produce many of these *N*-acyl lipids conjugated to short-chain fatty acids.

259
260 To assess the presence of *N*-acyl lipids and their potential changes under different
261 biological conditions, we performed in-depth analyses using our newly created library on

262 public datasets that had expanded metadata. Reanalysis of datasets on diabetes (type
263 I), various stages of forensic human body decompositions,³⁵ and diet and effect of
264 antibiotics in colorectal cancer³⁰ revealed the presence of many *N*-acyl lipids based on
265 matching their MS/MS against the MS/MS *N*-acyl lipids resource (**Figure 2E,F**,
266 **Supplementary Figure 3G-M**). Peak intensity analysis against the available metadata
267 revealed that shorter-chain *N*-acyl lipids were decreased in the diabetic group (urine from
268 humans) (**Supplementary Figure 3G**), longer-chain fatty acids *N*-acyl lipids increased
269 upon cadaver decomposition (skin swabs from humans and soil) (**Supplementary Figure**
270 **3H-K, Supplementary Figure 4D,E**), and overall *N*-acyl lipids levels were altered by diet
271 (feces of mice on normal chow vs. high fat diet) (**Figure 2E**). Mice on a normal chow had
272 a higher abundance and variety of short-chain fatty acid-derived *N*-acyl lipids compared
273 to mice on a high-fat diet. Conversely, mice on a high-fat diet showed increases in *N*-acyl
274 lipids conjugated to longer-chain fatty acids (**Figure 2E, Supplementary Figure 3L**).
275 Intriguingly, most of those same longer-chain fatty acid conjugates that are observed in
276 the high-fat diet are no longer detected upon treatment with an antibiotic cocktail (**Figure**
277 **2F, Supplementary Figure 3M**), providing additional evidence linking the production of
278 many of the *N*-acyl lipids conjugates to the microbiome and diet. After generating and
279 validating the *N*-acyl lipid resource with published datasets and with the new knowledge
280 that many *N*-acyl lipids are made by the microbiota, we next set out to demonstrate its
281 utility in a new human research study.

282

283 **Demonstrating the utility of the *N*-acyl lipid resource - *N*-acyl lipids in relation to** 284 **HIV, immune and cognition status.**

285 To further demonstrate the utility of our newly created *N*-acyl lipid MS/MS library,
286 and to provide a case study on how to leverage this resource, we used it to annotate *N*-
287 acyl lipids in an ongoing study in our laboratory aimed at understanding the effect of the
288 microbiome on cognition in people infected with the human immunodeficiency virus (HIV).
289 This cohort included stool data collected from both people with HIV (PWH) and people
290 without HIV (PWoH) who had also completed neurocognitive evaluations as part of NIH-
291 funded studies conducted at the UC San Diego HIV Neurobehavioral Research Program,
292 primarily the HIV Neurobehavioral Research Center (HNRC). More than 50 matches to
293 MS/MS spectra of *N*-acyl lipids were obtained, and we observed higher levels of
294 histamine *N*-acyl lipids, particularly those conjugated with short-chain fatty acids, in PWH
295 compared to PWoH (**Supplementary Figure 5A**). In pairwise comparisons of specific *N*-
296 acyl lipids, histamine-C2:0, histamine-C3:0, and histamine-C6:0 were higher in PWH
297 (Mann-Whitney U test, *p*-values of 0.003, 0.003, and 0.042, respectively). Besides that,
298 histamine-C4:0 and histamine-C5:0 also showed a higher trend in PWH. All other *N*-acyl
299 histamines, including those not initially searched for with the MassQL query but identified
300 through molecular networking,^{36–38} were found in higher average levels in samples of

301 PWH compared to PWOH (**Supplementary Figure 5B**). However, none of these lipids
302 reached significance at the selected statistical threshold of $p < 0.05$.

303

304 Histamine conjugates were linked to HIV status, while polyamine *N*-acyl lipids were
305 associated with neurocognitive impairment status (impaired vs. unimpaired). Specifically,
306 cadaverine and putrescine *N*-acyl lipids, particularly those with short acyl chains, were
307 elevated in the impaired group compared to the unimpaired group (Mann-Whitney U test,
308 p -values from 0.001 to 0.04, **Supplementary Figure 5C,D**). Further, analyses using a
309 linear mixed-effects model, with fixed covariates of HIV status and neurocognitive
310 impairment status, while treating the subject as a random effect, suggest that histamine-
311 C2:0 and histamine-C3:0 continue to be positively associated with HIV status and
312 acylated polyamines were associated with neurocognitive impairment (**Figure 3A**). We
313 also observed a trend where the histamine conjugates with C2, C3, C4, and C5, were
314 negatively associated with CD4⁺/CD8⁺ T cell ratio in PWH, which is an indicator of
315 immune system homeostasis.³⁹ In contrast, polyamines, particularly cadaverines linked
316 to C2, C3, C5, C6, and C7, tended to show a positive correlation with the CD4⁺/CD8⁺ ratio
317 in PWH (**Figure 3B**). Additionally, we explored the relationships between *N*-acyl lipids
318 and plasma HIV RNA viral loads in the PWH. We found that *N*-acyl lipids with short acyl
319 chains were positively associated with higher viral loads, while those with longer acyl
320 chains were linked to lower viral loads (**Supplementary Figure 5E**). To validate their
321 identities, we matched retention time and MS/MS in comparison to pure synthetic
322 standards for 13 of these short-chain fatty acid-derived *N*-acyl lipids that are associated
323 with HIV status (histamine-C2:0, C3:0, C4:0, C5:0, and C6:0), neurocognitive impairment
324 status (cadaverine-C2:0, C3:0, C5:0, C6:0, and C7:0), and included dopamine-C2:0,
325 serotonin-C2:0, and tryptophan-C3:0 in this validation of the annotations
326 neurotransmitters derivatives - even though they did not associate with neurocognitive
327 impairment (**Figure 3C**). All of the compounds matched both the retention times and the
328 MS/MS spectra in the fecal samples, confirming their presence in the samples
329 (**Supplementary Figure 5F,G**). Quantification revealed that many of these can be
330 present in high μM concentrations (**Supplementary Table S3**). Although we do not yet
331 understand the biology behind this variability, and many samples had concentrations
332 below the limit of quantification, the highest concentrations of *N*-acyl histamines that we
333 quantified were 93.8, 20.7, 7.0, and 2.7 ng/g of fecal sample for histamine-C2:0 through
334 histamine-C5:0, respectively. Additionally, for the *N*-acyl cadaverines, we found the
335 concentrations to be as high as 350.4, 126.7, 36.7, and 1.3 ng/g for cadaverine-C2:0,
336 cadaverine-C3:0, cadaverine-C5:0, and cadaverine-C6:0, respectively. Dopamine-C2:0
337 was also quantified, with levels ranging from 0.0008 to 3.2 ng/g. While histamine-C6:0,
338 cadaverine-C7:0, serotonin-C2:0, and tryptophan-C3:0 were matched with retention
339 times and MS/MS, their concentrations were too low to be accurately quantified in the
340 samples.

344 fixed covariates of HIV status (PWH, $n = 226$; PWoH, $n = 87$) and neurocognitive impairment status
345 (impaired, $n = 151$; unimpaired, $n = 162$), accounting for random effects within individual samples/visit.
346 Filled circles (HIV status) and squares (neurocognitive impairment status) with corresponding confidence
347 intervals represent significant *N*-acyl lipid species. Faded circles and squares depict non-significant
348 species. Each color represents a different headgroup. **(B)** Bar plot showing the correlation coefficients of
349 association between CD4/CD8 ratio and various *N*-acyl lipids in a subset of the PWH ($n = 171$) with
350 available metadata. Red bars represent positive correlations, while blue bars represent negative
351 correlations, as determined by linear regression models. The p-values shown are nominal; adjusted p-
352 values (corrected for multiple comparisons using the Benjamini-Hochberg method) are available in
353 **Supplementary Table S3**. **(C)** Structures of all *N*-acyl lipids confirmed in this study with pure synthetic
354 standards. **(D)** Microbe-metabolite co-occurrence biplot obtained from mmvec⁴⁰ analysis of the HNRC
355 sample. Spheres represent ions of molecules, while arrows represent microbes. Spheres were colored
356 based on which group (PWH vs. PWoH) each ion feature was most abundant in. Small angles between the
357 arrows indicate microbes co-occurring with each other, and spheres close in the plot represent features co-
358 occurring. Arrows pointing toward a group of molecules indicate microbe-molecule co-occurrence. This
359 biplot shows the 30 most important OTUs (higher vector magnitude). **(E)** Network of the microbial taxonomic
360 orders with co-occurrences > 6.0 and shared between histamine-C2:0 and histamine-C3:0. Nodes colored
361 in pink are the orders selected for culturing experiments.

362

363 **Microbial producers of HIV-associated histamine *N*-acyl lipids.** Samples from the
364 HNRC also underwent metagenomic sequencing, allowing us to perform correlation
365 analyses to identify microbes potentially responsible for producing the histamine and
366 polyamine *N*-acyl lipids associated with HIV and neurocognitive status. Previous microbial
367 cultures from this study produced cadaverine-C2:0 and cadaverine-C4:0
368 (**Supplementary Figure 3F**). MicrobeMASST searches also confirmed that cadaverine
369 *N*-acyl lipids have been observed in microbial monocultures (**Figure 1B**). However, no
370 microbial *N*-acyl histamines were detected in either public data or our experiments, raising
371 the question of whether histamine conjugates are microbially produced, and if so, which
372 microorganisms may be responsible for their production.


373

374 To investigate this further and identify microbes potentially associated with *N*-acyl
375 histamines, we conducted a multiomic microbe-metabolite co-occurrence analysis using
376 mmvec.⁴⁰ We observed a strong trend of distinct microbe-metabolite co-occurrences
377 between PWH and PWoH (**Figure 3D**). Higher microbial-metabolite co-occurrence
378 probabilities were observed for histamine-C2:0 and histamine-C3:0 (**Supplementary**
379 **Table S3**). Ten microbial taxonomic orders also stood out for presenting several
380 organisms that resulted in high co-occurrence probabilities with both histamine-C2:0 and
381 histamine-C3:0, with histamine-C2:0 exhibiting more high co-occurrences than histamine-
382 C3:0 (**Figure 3E**).

383

384 Based on the multiomics analysis and availability of strains, we selected nine
385 bacterial strains from these microbial orders for culturing and supplemented the media
386 with histamine, cadaverine, and putrescine. After 72 h of culturing, we analyzed the

387 samples using LC-MS/MS and matched them against the *N*-acyl lipids library (**Figure 4**).
388 We identified histamine-C2:0, histamine-C3:0, cadaverine-C2:0, and cadaverine-C3:0 in
389 the cultures at 72 h, whereas these compounds were not detected at 0 h post-addition.
390 This finding confirmed that some microorganisms were capable of producing these *N*-
391 acyl lipids. Specifically, cadaverine-C3:0 was observed in cultures of *Collinsella*
392 *aerofaciens* ATCC 25986 and *Prevotella buccae* D17, while cadaverine-C2:0 was
393 detected in extracts from these two microbes as well as in *Catenibacterium mitsuokai*
394 DSM 15897 and *Holdemanella bififormis* DSM 3989. *Catenibacterium mitsuokai* DSM
395 15897 produced only histamine-C2:0, whereas *Collinsella aerofaciens* ATCC 25986,
396 *Holdemanella bififormis* DSM 3989, and *Prevotella buccae* D17 produced both histamine-
397 C2:0 and histamine-C3:0. *Dorea longicatena* DSM 13814 produced only histamine-C3:0.
398 *Collinsella aerofaciens* ATCC 25986 produced the highest amount of histamine-C2:0,
399 with a concentration of $1.905 \pm 0.302 \mu\text{M}$ in the extracts (**Figure 4A, Supplementary**
400 **Table S4**). The highest levels of histamine-C3:0 were observed in *Prevotella buccae* D17,
401 with a concentration of $0.358 \pm 0.016 \mu\text{M}$ (**Figure 4B, Supplementary Table S4**).
402 Cadaverine-C2:0 and cadaverine-C3:0 were confirmed to be produced by specific
403 microbes by MS/MS and retention time matching, but these compounds were present in
404 lower concentrations in the extracts and could not be accurately quantified.
405



406 **Figure 4. Evidence of microbial production of *N*-acylated histamines.** Concentrations of (A) histamine-
407 C2:0 and (B) histamine-C3:0 in microbial extracts. Values in the y-axis represent the amount of these
408 compounds in micromolar (μM) concentrations in the extracts. Cadaverine (C), putrescine (P) and
409 histamine (H) were added to the medium.
410
411

412 Discussion:

413 Despite their infrequent description or annotation in metabolomics data and
414 literature, *N*-acyl lipids are quite prevalent, as revealed by our reverse metabolomics
415 analysis using the MassQL-generated MS/MS reference resource. A significant portion
416 of the *N*-acyl lipids identified in this study were derived from short-chain fatty acids. Free
417 short-chain fatty acids are a key and extensively studied class of molecules produced at
418 the microbiota-diet interface.⁴¹ While primarily produced in the gut, these fatty acids can
419 impact distant organs such as the liver, lungs, urogenital tract, and brain.⁴²⁻⁴⁴ They play

420 a role in immune regulation, affecting T-cell functions, CD4⁺/CD8⁺ levels, and are
421 implicated in health conditions like disrupted intestinal barrier function, and diseases,
422 including autoimmune disorders, diabetes, and HIV.^{41,45,46}

423

424 Given the short-chain fatty acids prominence in microbiome research, it was
425 surprising to find such a large panel of *N*-acyl lipids, many derived from short-chain fatty
426 acids, that had not been previously documented in lipid structural data resources. Our
427 study demonstrated that these *N*-acyl lipids are detected in data from sites distant from
428 the gut. Their levels are influenced by factors such as dietary changes, antibiotic use, and
429 health conditions affecting the microbiome, such as diabetes, and other microbiome-
430 mediated processes such as decomposition. Additionally, analysis of publicly available
431 data, along with microbial culturing experiments conducted in this study, showed that
432 individual cultures can produce, in a microbe-specific manner, certain *N*-acyl lipids when
433 both the amine headgroup and lipid substrates are present.

434

435 Data from fecal samples of people with HIV revealed a substantial number of
436 microbially produced short-chain fatty acid-derived *N*-acyl lipids—an observation not
437 previously identified despite numerous metabolomics studies on PWH.^{47–54} This
438 discovery was made possible by the *N*-acyl lipid MS/MS resource created in this work.
439 We found that microbially produced short-chain fatty acids linked to polyamines and
440 histamine were associated with plasma HIV RNA viral load and CD4⁺/CD8⁺ levels in
441 PWH. This study uncovered several *N*-acylated lipids related to HIV status, including
442 histamine conjugates, while many polyamine-derived *N*-acyl lipids were associated with
443 neurocognitive impairment status in both people with and without HIV in this cohort.

444

445 Although limited information is available on histamine-containing *N*-acyl lipids, it is
446 known that the non-acylated histamine itself, produced by macrophages, is increased in
447 people with HIV.⁵⁵ Thus, one can hypothesize that the production of the *N*-acylated
448 histamines may require not only the availability of histamine but also the short-chain fatty
449 acids and the right organisms. Indeed, organisms such as *Prevotella*, which are
450 commonly enriched in PWH,⁵⁶ can produce propionate from succinate⁵⁷ and have the
451 ability to couple this to histamine. Beyond HIV populations, very little is known about the
452 short-chain fatty acid-histamine conjugates. The C2 and C3 *N*-acyl histamines were
453 previously found to be elevated in the urine of patients with intestinal disorders, the
454 histamine-C6 was found to be very modestly cytotoxic while related molecules that have
455 longer chain fatty acids conjugated to them act on peroxisome proliferator-activated
456 receptor- α (PPAR- α).^{58–60} PPAR- α protects from HIV-related systemic inflammation and
457 improves intestinal barrier function.^{61,62} We did not find biological reports for the C4-C5
458 histamine conjugates, and it is not yet known if these specific *N*-acyl lipids also provide
459 such protective effects.

460

461 There is a strong connection between HIV disease and polyamines. Polyamines,
462 such as cadaverine, protect the HIV virion and sperm from the acidity in the vaginal tract
463 and increase infectivity.⁶³ Polyamines are detected in higher quantities and affect T_{reg} cell
464 dysfunction in people with HIV.^{48,64,65} Intriguingly, polyamine metabolism plays a crucial
465 role in maintaining the integrity of helper T cell lineage, which is crucial in regulating
466 inflammation and maintaining immune tolerance.^{66,67} As with the histamine conjugates,
467 there is also limited information on polyamine conjugates and HIV disease or other health
468 conditions. This includes the cadaverine *N*-acyl lipids, except for the commonly measured
469 C2-conjugate, which has been associated with cancer and other health conditions, such
470 as in the urine of individuals with Alzheimer's disease and has been shown to reduce the
471 aggressiveness of breast cancer in rodents.^{68–70} The cadaverine-C3, also known as *N*-
472 propionyl cadaverine, has been shown to reach the brain of rats *in vivo* but also, as shown
473 *in vitro*, depresses electrically stimulated dopamine release from the neostriatum from
474 rats at concentrations in the nM range.^{71–73} We did not find biological reports for the C4-
475 C6 cadaverine, despite recent studies highlighting the discovery of microbiome-derived
476 polyamines.^{22,74–76} We found polyamine *N*-acyl lipids, especially cadaverine short-chain
477 fatty acid conjugates, are associated with impairment status in this study, a new finding,
478 although it is established that other polyamines, acetyl-spermidine, and unconjugated
479 putrescine, are biomarkers for HIV-associated neurocognitive disorders,⁷⁷ this is not
480 known for the *N*-acyl-cadaverines.

481

482 Non-dietary histamine and cadaverine levels are reported to be inversely linked,
483 and we see a similar trend for the *N*-acyl cadaverine and histamines and in relation to
484 CD4⁺/CD8⁺ ratio. Although it is not yet known if *N*-acyl conjugates exhibit similar activities,
485 cadaverine can potentiate histamine levels, possibly via competitive inhibition of
486 histamine-degrading enzymes.^{78–80} This inverse relationship and the role of the
487 *Prevotella*-derived production of short-chain fatty acid-linked histamine and polyamines
488 and their role in HIV disease and HIV-associated neurocognitive impairment warrants
489 more research. However, without the *N*-acyl lipid reference resource provided by this
490 work, the observation that these microbial-derived molecules and their associations with
491 HIV disease and HIV neurocognitive impairment would have remained hidden.

492 The unexpected discovery of hundreds of short-chain fatty acid-derived *N*-acyl
493 lipids, not reported in structural lipid databases, highlights their widespread presence
494 across all biofluids and organs for which data is available, despite most being produced
495 by the microbiota. The identification of various structural family members opens an
496 additional chapter in understanding the mechanistic and functional roles of short-chain
497 fatty acids. This finding may even prompt a reinterpretation of how microbially produced
498 short-chain fatty acids influence the production of *N*-acyl lipids, and consequently, a wide
499 range of conditions, as they are only formed when both substrates are present and the

500 appropriate microbe(s) are present to create the link. This resource has enabled the
501 generation of numerous hypotheses regarding the functions of these *N*-acyl lipids, and
502 we anticipate that fully elucidating their roles will require extensive research across many
503 laboratories and thousands of studies.

504 While we provide signatures for 851 metabolites here, this is only the beginning.
505 Many other amines are not covered in this study and they also may be linked to different
506 fatty acids. Lipids containing other atoms, such as oxygen, nitrogen, or halogens, were
507 not included and would require dedicated MassQL queries or the development of
508 alternative detection strategies. Alcohols might also undergo similar structural
509 diversification. Moreover, the diversity of lipids available for acylation extends well beyond
510 the C2:0 to C30:4 range of lipids we examined. We anticipate that this resource will spur
511 the development of additional ways to find *N*-acyl lipids and will help uncover additional
512 biological and health associations. This may enhance our understanding of microbiome-
513 mediated effects and potentially serve as easy-to-detect microbial biomarkers in precision
514 medicine, given their prevalence. Finally, this resource captures the intersection of
515 nutrient availability with microbial and host metabolism, warranting further exploration as
516 regulators of the immune system.

517

518 **Limitations of the study:**

519 Users of this resource should consider three main limitations when making
520 biological discoveries. First, while we have consistently matched the MS/MS of synthetic
521 standards to MassQL recovered spectra, there have been instances where the match
522 was to a different isomer. For example, in the cohort of the body decomposition study,
523 there were compounds, such as the amylamine conjugates, that the MS/MS spectra
524 matched the standard, but the retention times did not align, suggesting the presence of a
525 different isomer instead, such as a branched chain in the acyl portion. Other headgroups
526 can also have more than one position for the acyl attachment, which will also result in
527 very similar MS/MS spectra. For the HIV study, all the pure *N*-acyl lipid standards matched
528 the compounds present in the samples. Even though there were three nitrogen atoms
529 available for the acyl substitution, the substitution of the acyl chain was observed in the
530 primary amine group in all cases. Therefore, at the repository level search, it is advisable
531 to refer to the number of carbons and double bonds in the lipid chain rather than the exact
532 structure, as multiple isomers can correspond to the same family of molecules (see
533 **Figure 1a**).

534

535 Secondly, our initial query was designed to capture the protonated ion forms of the
536 molecules. However, many different ion forms, such as adducts, multimers, and in/post-
537 source fragments, are commonly detected for any given molecule. The fragmentation
538 patterns of other ion forms may differ and would require separate MassQL queries. A
539 limitation of using other ion forms for query development is the scarcity of reference

540 spectra to understand their fragmentation behavior. Nevertheless, once an annotation is
541 made, it is possible to retrieve associated MS/MS spectra for different ion forms through
542 peak shape and retention time alignments.⁸¹ Currently, this type of analysis is feasible
543 only within a single dataset and not across all public data simultaneously.

544
545 Finally, it is crucial to note that our observations are based on the *N*-acyl lipid
546 spectra detected in public-domain data. Biological associations can only be established
547 when there is well-curated public (meta)data. Variations in underlying biological
548 conditions—such as feeding time, health, circadian rhythm, and diet type—may affect
549 concentrations and detectability in untargeted metabolomics. Moreover, mass
550 spectrometry-based metabolomics data are highly sensitive to data acquisition
551 parameters (e.g., mass spectrometer type, ionization technique, collision energies,
552 chromatographic gradient) and sample preparation methodologies (e.g., storage
553 conditions, extraction methods). Therefore, while the observed patterns and trends in *N*-
554 acyl lipid distribution across various tissues and biofluids provide valuable insights, they
555 should be interpreted with these considerations in mind and use the results to formulate
556 testable hypotheses.

557
558 **Acknowledgments:** We thank the support by NIH (NIDDK) for the development of tools
559 for structure elucidation R01DK136117, the Collaborative Microbial Metabolite Center
560 U24DK133658, and the HIV Neurobehavioral Research Center (HNRC) is supported by
561 Center award P30MH062512 from NIMH. This work was further supported by BBSRC-
562 NSF award 2152526. Research reported in this publication was supported in part by the
563 National Center for Complementary and Integrative Health of the NIH under award
564 number F32AT011475 to N.E.A., the Maternal and Pediatric Precision in Therapeutics
565 project P50HD106463. X.S. was supported by the National Key R&D Program of China
566 2022YFA0807300, 2023YFA1800200, NSF of China 32270945, STCSM 22ZR1468700,
567 and 22140902400. S.L. was supported by Research Council of Finland funding (no.
568 363417 to S.L.). J.J.K. was supported by the NIH CTSA grant UL1TR001442 and the
569 UCSD Microbiome Seed Grant. M.R. was supported by NIH grant R37AI126277. G.T.W.
570 was supported by NIH training grant T32AI007036. G.J.N. was supported by NIH
571 fellowship F31AI186410. We also thank Dr. Jessica L. Metcalf for the supervision of the
572 human cadaver decomposition study and Dr. Robert Heaton for the participation in the
573 development of the clinical cohort of human immunodeficiency virus (HIV) infection.

574
575 **Author contributions:**
576 P.C.D. conceptualized the project. H.M-R. and M.F. developed the MassQL queries and
577 performed the repository-scale searches. H.M-R. created the *N*-acyl lipids library. H.M-R,
578 S.L., W.D.G.N., L.K., P.R., H.N.Z, and P.W.P.G. performed data analysis. V.C-L., G.W.,
579 G.N., L.C., C.W., and S.R. performed microbial incubation experiments. K.Z., M.R., and

580 L.B. supervised the culturing experiments. H.M-R., V.C-L., W.D.G.N., J.Z., and M.J.M.
581 acquired LC-MS/MS data. V.D., A.P., K.V., I.M., C.L., A.S., M.S., Y.L., and D.P.
582 performed the combinatorial synthesis reactions. P.C.D. and D.S. supervised the
583 synthesis. M.S.A., R.J.E., D.J.M, J.E.I., D.F.Jr, and S.L. developed the clinical cohort of
584 human immunodeficiency virus (HIV) infection. M.S.A. and C.X.W. assisted with data
585 interpretation. Y.E.A. performed database searches. M.W. provided support for MassQL
586 searches. X.S. and D.K. supervised the monocolonized mice study. J.K. and S.K.
587 supervised the diabetes study. Z.B. supervised the human decomposition study. R.K.
588 supervised sample handling and DNA data acquisition for the HNRC cohort. H.M-R. and
589 P.C.D. drafted the manuscript. P.C.D. acquired funding and supervised this project. All
590 authors reviewed and edited the manuscript.

591
592 **Declaration of interests:**
593 PCD: PCD is an advisor and holds equity in Cybele, BileOmix and Sirenas and a Scientific
594 co-founder, advisor and holds equity to Ometa, Enveda, and Arome with prior approval
595 by UC-San Diego. PCD also consulted for DSM animal health in 2023. MW: MW is a co-
596 founder of Ometa Labs LLC. RK: Rob Knight is a scientific advisory board member, and
597 consultant for BiomeSense, Inc., has equity and receives income. He is a scientific
598 advisory board member and has equity in GenCirq. He is a consultant for DayTwo, and
599 receives income. He has equity in and acts as a consultant for Cybele. He is a co-founder
600 of Biota, Inc., and has equity. He is a cofounder of Micronoma, and has equity and is a
601 scientific advisory board member. The terms of these arrangements have been reviewed
602 and approved by the University of California, San Diego in accordance with its conflict of
603 interest policies.

604
605 **Main Figure titles and legends:**
606 **Figure 1. Repository-scale analysis of *N*-Acyl lipids in public mass spectrometry**
607 **data and distribution among different tissues or biofluids. (A) *N*-acyl lipid definitions**
608 **and isomers:** this panel explains *N*-acyl lipids using a C5:1 tail example. A C5:1 lipid
609 consists of a five-carbon fatty acid with one double bond. The image illustrates the
610 possible isomers for this structure that can yield the same MS/MS spectrum. **(B) Heatmap**
611 **of *N*-acyl lipids:** the heatmap shows 851 *N*-acyl lipids identified from public MS data in the
612 MassIVE/GNPS repository using MassQL queries.²⁰ Validation of the data was performed
613 using cosine similarity (see **Supplementary Figure 1E**). Compounds found in microbial
614 cultures are marked with purple squares, those matched with synthetic standards are
615 indicated by black stars, and those confirmed by retention time with biological samples
616 are shown with red stars. **(C) and (D) Heatmaps showing distribution in tissues and**
617 **biofluids:** number of matches of different fatty acid chain lengths in tissues and biofluids
618 with metadata available in ReDU¹⁹ for **(C)** rodent and **(D)** human-related public datasets.

619 All heatmaps are shown as log values of the matches obtained from the repository,
620 regardless of the headgroup. Icons were obtained from Bioicons.com.

621 **Figure 2. Evidence of microbial origins of *N*-acyl lipids.** Heatmaps depict the
622 distribution of different headgroups (**A**) and tails (**B**) across various microbial classes, with
623 barplots showing the total counts for each class in microbeMASST.¹⁵ The Y-axis was
624 taxonomically ordered according to the NCBI Taxonomy ID, while the X-axis was
625 clustered using the Braycurtis metric for the headgroups, or in ascending order (in number
626 of carbons and unsaturations) for the tails. **C**) UpSet plot of *N*-acyl lipid distribution: This
627 plot highlights the distribution of *N*-acyl lipids across different datasets, including human-
628 related, rodent-related, microbial monocultures, plant-, and food-associated data. **D**)
629 Distribution of *N*-acyl lipid chain lengths: This summary shows the prevalence of short,
630 medium, long, and very long chain *N*-acyl lipids in public data. Note that the exact location
631 and cis/trans configurations of double bonds cannot be determined from the current
632 queries, which are annotated at the molecular family level according to the Metabolomics
633 Standards Initiative.²⁷ **E** and **F**) Volcano plots of mouse fecal pellets from a dataset
634 publicly available (GNPS/MassIVE: [MSV000080918](#))³⁰ showing *N*-acyl lipids up-
635 regulated and down-regulated upon different diets (**E**) and antibiotic treatment (**F**). The
636 significant thresholds are marked by dotted lines in the volcano plot ($p < 0.05$ and
637 $\log_2(\text{FC}) > 2$ or < 2). Differential compounds between the groups were evaluated using
638 the non-parametric two-sided Mann-Whitney U test, and p-values were corrected for
639 multiple comparisons using the Benjamini-Hochberg correction. Icons were obtained from
640 Bioicons.com.

641
642 **Figure 3. *N*-acyl lipids are correlated with HIV and neurocognitive impairment**
643 **status.** (**A**) Forest plot illustrating the coefficient estimate of a linear mixed-effects model
644 for individual *N*-acyl lipid species, with fixed covariates of HIV status (PWH, $n = 226$;
645 PWoH, $n = 87$) and neurocognitive impairment status (impaired, $n = 151$; unimpaired, n
646 $= 162$), accounting for random effects within individual samples/visit. Filled circles (HIV
647 status) and squares (neurocognitive impairment status) with corresponding confidence
648 intervals represent significant *N*-acyl lipid species. Faded circles and squares depict non-
649 significant species. Each color represents a different headgroup. (**B**) Bar plot showing the
650 correlation coefficients of association between CD4/CD8 ratio and various *N*-acyl lipids in
651 a subset of the PWH ($n = 171$) with available metadata. Red bars represent positive
652 correlations, while blue bars represent negative correlations, as determined by linear
653 regression models. The p-values shown are nominal; adjusted p-values (corrected for
654 multiple comparisons using the Benjamini-Hochberg method) are available in
655 **Supplementary Table S3.** (**C**) Structures of all *N*-acyl lipids confirmed in this study with
656 pure synthetic standards. (**D**) Microbe-metabolite co-occurrence biplot obtained from
657 mmvec⁴⁰ analysis of the HNRC sample. Spheres represent ions of molecules, while
658 arrows represent microbes. Spheres were colored based on which group (PWH vs.

659 PWOH) each ion feature was most abundant in. Small angles between the arrows indicate
660 microbes co-occurring with each other, and spheres close in the plot represent features
661 co-occurring. Arrows pointing toward a group of molecules indicate microbe-molecule co-
662 occurrence. This biplot shows the 30 most important OTUs (higher vector magnitude).
663 (E) Network of the microbial taxonomic orders with co-occurrences > 6.0 and shared
664 between histamine-C2:0 and histamine-C3:0. Nodes colored in pink are the orders
665 selected for culturing experiments.

666
667 **Figure 4. Evidence of microbial production of *N*-acylated histamines.** Concentrations
668 of **A)** histamine-C2:0 and **B)** histamine-C3:0 in microbial extracts. Values in the y-axis
669 represent the amount of these compounds in micromolar (μM) concentrations in the
670 extracts. Cadaverine (C), putrescine (P) and histamine (H) were added to the medium.

671
672 **Supplementary figure titles and legends:**

673
674 **Supplementary Figure 1. Distribution of *N*-acyl lipids in structural databases and**
675 **mass spectrometry repository searches, related to Figure 1. A)** Diversity and relative
676 frequency of *N*-acyl lipids headgroups and **(B)** lipid chain lengths documented in LIPID
677 MAPS. This analysis excludes ceramide acylations. **C)** *N*-acyl lipid query strategy:
678 representative MS/MS spectrum of phenylalanine-C10:0 (CCMSLIB00011435104) and
679 phenylalanine-C16:0 (CCMSLIB00011435452). The spectra show nearly identical
680 fragmentation patterns enabling the creation of the MassQL query to retrieve the MS/MS
681 spectra of this family of lipids. **D)** MassQL query for phenylalanine headgroup where we
682 initiate to return all MS/MS spectra (in yellow) that fulfill the following criteria: the precursor
683 ion has to match one of the expected precursor *m/z* values specified (gray), as well as
684 the most diagnostic *m/z* fragments of the head portion (blue and pink) with their indicated
685 error tolerances and minimum relative intensities. **E)** Strategy followed to create the *N*-
686 acyl lipids library and expand to biological interpretations. (I) MassQL queries were
687 designed and run against the Orbitrap datasets in the GNPS/MassIVE repository. (II) The
688 spectra were clustered using MSCluster to reduce redundancy. (III) A cosine similarity
689 filter was applied to keep the higher confidence *N*-acyl lipids spectra. (IV) The clustered
690 spectra were searched using FASST searches against the whole repository (including
691 Orbitrap and QToF datasets), and human and rodent-related datasets were tagged using
692 ReDU, and microbial, plant, and food-related datasets were also tagged using domain-
693 specific MASSTs. (V) The spectra retrieved from the FASST searches were filtered to
694 keep the matches in which the raw (unfiltered) spectra resulted in cosine similarity above
695 0.7. (VI) Summary of the results obtained with this workflow. Icons were obtained from
696 Bioicons.com.

697

698 **Supplementary Figure 2. Distribution of *N*-acyl lipids obtained from FASST**
699 **searches among different tissues or biofluids, related to Figure 1.** Summary of the
700 occurrences in the public domain in (A) human and (B) rodent-related datasets.
701 Heatmaps show the distribution of the number of matches grouped by headgroup in
702 different tissues and biofluids with metadata available in ReDU for (C) human and (D)
703 rodent-related public datasets. All heatmaps are shown as log values of the matches
704 obtained from the repository. Icons were obtained from Bioicons.com.

705
706 **Supplementary Figure 3. *N*-acyl lipids chain length diversity, evidence of microbial**
707 ***N*-acyl lipids, and reanalysis of public datasets, related to Figure 2.** Distribution of *N*-
708 acyl lipids in public data stratified by chain length classes. Upset plots show the number
709 of unique *N*-acyl lipids attached to (A) short, (B) medium, (C) long, and (D) very long
710 chain fatty acids. (E) Reanalysis of a public dataset of monoclonized GF mice
711 (GNPS/MassIVE: [MSV000088040](#), deposited in 2021)^{31,32}. Heatmap log₂ fold changes
712 (FCs) of the *N*-acyl lipids matches in colon and small intestine samples of monoclonized
713 mice relative to germ-free (GF) mice. Values of the diet, Specific Pathogen Free (SPF)
714 mice, and of mice colonized with Segmented Filamentous Bacteria (SFB) are also shown.
715 Red cells indicate compounds that are increasing relative to GF, while blue cells indicate
716 compounds that are decreasing relative to GF mice. The x-axis is taxonomically ordered
717 according to the NCBI Taxonomy ID. (F) Heatmap showing the log₂ fold change of *N*-
718 acyl lipids matches in microbial monocultures of gut commensal microbes relative to the
719 culture media. Red cells indicate compounds that are increasing, while blue cells indicate
720 compounds that are decreasing relative to the media. The x-axis is taxonomically ordered
721 according to the NCBI Taxonomy ID. (G) Peak area abundances of *N*-acyl lipids
722 annotated in a public dataset (GNPS/MassIVE: [MSV000082261](#)) from urine samples
723 across clinical groups of healthy and type I diabetes mellitus. Only *N*-acyl lipids with *p*-
724 values of 0.05 or less are shown. Healthy, *n* = 52; Diabetes (type 1), *n* = 44. (H,I) *N*-acyl
725 lipids annotated from a public dataset (GNPS/MassIVE: [MSV000084322](#),
726 [MSV000084463](#)) of (H) skin swabs and (I) soil samples of a human cadaver
727 decomposition study.³⁵ The parallel coordinates plots show the mean of the *N*-acyl lipids
728 peak areas obtained for the different headgroups in each of the stages of decomposition.
729 Each line represents a *N*-acyl lipid match. (J,K) Peak area abundances of *N*-acyl lipids
730 annotated in public datasets from (J) skin (GNPS/MassIVE: [MSV000084322](#)) and (K) soil
731 (GNPS/MassIVE: [MSV000084463](#)) samples across different stages of decomposition of
732 human bodies.³⁵ Skin: Day0, *n* = 36; Early, *n* = 171; Active, *n* = 292; Advanced, *n* = 249.
733 Soil: Day0, *n* = 36; Early, *n* = 171; Active, *n* = 299; Advanced, *n* = 252. (L,M) Peak area
734 abundances of *N*-acyl lipids annotated in a public dataset (GNPS/MassIVE:
735 [MSV000080918](#))³⁰ from mice fecal samples of mice subjected to different diets (L) and
736 treatment with a cocktail of antibiotics (M). Antibiotics: No, *n* = 310; Yes, *n* = 27. Diet:
737 HFD, *n* = 310; NC, *n* = 114. For the antibiotics plot, only mice fed with HFD were

738 considered. All boxplots indicate the first (lower), median, and third (upper) quartiles,
739 while whiskers are 1.5 times the interquartile range. Significance was tested in cases
740 where two groups were compared using the non-parametric two-sided Mann-Whitney U
741 test, while for more than two groups the non-parametric Kruskal-Wallis test was used,
742 and p-values were corrected for multiple comparisons using the Benjamini-Hochberg
743 correction. Compounds with p-values below 0.05 are highlighted in red. Icons were
744 obtained from Bioicons.com.

745
746 **Supplementary Figure 4. MS/MS and retention time matching of *N*-acyl lipids in**
747 **samples from the microbial monocultures and from the body decomposition study,**
748 **related to Figure 2. (A)** MS/MS mirror plots and retention time matches to *N*-acyl lipids
749 obtained via combinatorial synthesis. MS/MS spectra on the top (black) represent spectra
750 detected in the microbial monocultures experiment (**Supplementary Figure 3F**). An
751 unusual series of *N*-acyl 2-phenethylamines was observed and confirmed in level 1
752 annotation^{27,28} in two different chromatographic methods: LC1 (**A**) and LC2 (**B**) - see
753 **Methods**. Chromatographic traces represent the exported ion chromatograms for each
754 compound (black: sample; green: standard). (**C**) MS/MS mirror plots and retention time
755 matches to *N*-acyl lipids obtained via combinatorial synthesis. MS/MS spectra on the top
756 (black) represent spectra detected in the body decomposition study (**Supplementary**
757 **Figure 3H-K**). Chromatographic traces represent the exported ion chromatograms for
758 each compound (black: sample; green: standard) in two different chromatographic
759 methods: LC1 (**C**) and LC2 (**D**) - see **Methods**. MS/MS mirror plots can be interactively
760 inspected in the Metabolomics Spectrum Resolver⁸² with the information provided in
761 **Supplementary Table S2**.

762
763 **Supplementary Figure 5. *N*-acyl lipids associated with HIV status, HIV plasma viral**
764 **load, and neurocognitive impairment status, related to Figure 3. (A)** Peak area
765 abundances of *N*-acyl histamines in people with HIV (PWH) and people without HIV
766 (PWoH) (PWH, $n = 228$; PWoH, $n = 93$). (**B**) Molecular network obtained for histamine *N*-
767 acyl lipids. (**C**) Peak area abundances of *N*-acyl polyamines in cognitively impaired and
768 normal participants (impaired, $n = 151$; unimpaired, $n = 162$) of the HNRC. (**D**) Molecular
769 network obtained for *N*-acyl cadaverines. Boxplots indicate the first (lower), median, and
770 third (upper) quartiles, while whiskers are 1.5 times the interquartile range. Significance
771 was tested using the non-parametric two-sided Mann-Whitney U test. The p-values
772 shown are nominal p-values, and the adjusted ones (for multiple comparisons using
773 Benjamini-Hochberg) are also available in **Supplementary Table S3**. The molecular
774 networks were created using the Feature-Based Molecular Networking workflow⁸³ within
775 the GNPS environment²¹. The nodes are annotated based on spectral similarity matches
776 with the *N*-acyl lipids library created. The nodes represent each MS/MS spectrum, while
777 the edges connecting them represent their spectral similarity (threshold set to cosine >

778 0.7). Pie charts indicate the relative abundance of ion features in each group highlighted.
779 This dataset is publicly available in GNPS/MassIVE under the accession number
780 [MSV000092833](#). (E) Bar plots showing the correlation coefficients for the association
781 between HIV RNA viral load and various *N*-acyl lipids in the PWH (n = 203). Red bars
782 represent positive correlations, while blue bars represent negative correlations, as
783 determined by linear regression models. The p-values shown are nominal; adjusted p-
784 values (corrected for multiple comparisons using the Benjamini-Hochberg method) are
785 available in **Supplementary Table S3**. (F) MS/MS mirror plots and retention time
786 matches to the pure *N*-acyl lipids standards. MS/MS spectra on the top (black) represent
787 the ones detected in the HNRC fecal samples, while the MS/MS on the bottom (green)
788 are the ones obtained from the standards. Chromatographic traces represent the
789 exported ion chromatograms for each compound (black: sample; green: standard). The
790 chromatographic method LC1 (see **Methods**) was used. MS/MS mirror plots can be
791 interactively inspected in the Metabolomics Spectrum Resolver⁸² with the information
792 provided in **Supplementary Table S3**. (G) Chromatographic traces represent the
793 exported ion chromatograms for each compound (black: sample; green: standard), with
794 data acquired in a different chromatographic method: LC2 (see **Methods**).

795

796

797

798 **STAR Methods:**

799

800 **Resource availability**

801

802 ***Lead contact***

803 Further queries and reagent requests may be directed and will be fulfilled by the lead
804 contact, Pieter C. Dorrestein (pdorrestein@health.ucsd.edu).

805

806 ***Materials availability***

807 This study did not generate new unique reagents. All the reagents in this study were
808 included in the key resources table.

809

810 ***Data and code availability:***

811 The *N*-acyl lipids library is available as part of the GNPS public spectral libraries
812 ([https://gnps.ucsd.edu/ProteoSAFe/gnpslibrary.jsp?library=GNPS-N-ACYL-LIPIDS-](https://gnps.ucsd.edu/ProteoSAFe/gnpslibrary.jsp?library=GNPS-N-ACYL-LIPIDS-MASSQL)
813 [MASSQL](https://gnps.ucsd.edu/ProteoSAFe/gnpslibrary.jsp?library=GNPS-N-ACYL-LIPIDS-MASSQL)), and is also archived in Zenodo (<https://doi.org/10.5281/zenodo.14015198>). All
814 the scripts used to perform the data analyses and generate the figures are available at
815 https://github.com/helenamrusso/N-acyl_lipids. NMR data of the pure *N*-acyl lipids has
816 been archived at Zenodo (<https://doi.org/10.5281/zenodo.14015081>). All the untargeted
817 metabolomics LC-MS/MS data are deposited on GNPS/MassIVE and publicly available

818 under the following accession numbers: MSV000088040 (monocolonized germ-free
819 mice), MSV000082261 (diabetes), MSV000084322 (body decomposition, skin) and
820 MSV000084463 (body decomposition, soil), diet and antibiotics treatment
821 (MSV000080918), MSV000095648 (microbial monocultures), MSV000092833 (HIV
822 study), MSV000095423 (retention time and MS/MS matching), and MSV000096049
823 (method validation and quantification). Due to human volunteer projection constraints, the
824 sample metadata for the HNRC cohort will be provided upon request to HNRC:
825 <https://hnrc.hivresearch.ucsd.edu/index.php/hnrc-home>.

826

827 **Experimental model and study participant details**

828 All procedures involving human participants adhered to the ethical standards established
829 by the institutional and/or national research committee (UCSD Human Research
830 Protections Program, HNRC IRB#172092).

831

832 **Method details**

833

834 ***Searches in LIPID MAPS***

835 An initial search in LIPID MAPS¹⁰ was performed searching for any compound in the
836 database that would have an amide bound, which resulted in 5,648 substructures.
837 Ceramides were filtered out, resulting in a total of 1,240 compounds that comprised a
838 mixture of fatty acid-derived *N*-acyl lipids, bile acid amidates, lipids attached to CoA, and
839 *N*-acylated molecules, such as deferioxamine and other natural products. These
840 compounds were that were manually inspected to determine if these were *N*-acyl lipids
841 (**Supplementary Table S1**). The headgroups and acyl chain lengths were plotted
842 (**Supplementary Figure 1A,B**) using the "seaborn.barplot" package (version 0.12.2) in
843 Python (version 3.7.6).

844

845 ***Design of the MassQL queries and creation of the *N*-acyl lipids library***

846 *N*-acyl lipids were searched in the GNPS/MassIVE public datasets, which consist
847 of ~1.2 billion spectra, and 2,706 datasets when this search was performed in 2023. This
848 search was initially conducted with Orbitrap public data deposited in the GNPS/MassIVE
849 repository using the Mass Spec Query Language (MassQL)²⁰. MassQL enables the
850 filtering of public mass spectrometry data to retrieve all MS/MS spectra that contain
851 defined and recognizable data patterns, and can also be done at the repository level.
852 Since *N*-acyl lipids ionize well in positive ionization mode and more than 90% of the public
853 mass spectrometry data was acquired in this mode, only positive ionization data was
854 mined from the public domain.

855

856 The queries were developed for biologically relevant molecules conjugated to an
857 acyl lipid chain via an amide bond (**Figure 1A**). The headgroups contained a primary or

858 secondary amine. In total, queries were designed for 64 heads, including proteinogenic
859 amino acids, polyamines, endocrine hormones, neurotransmitters, and other selected
860 diagnostic-relevant metabolites, ranging from serotonin to kynurenine, and from thyroxine
861 (T4) to glutathione (see **Supplementary Table S1** for the complete list of molecules for
862 which a query was developed). We directed our searches to compounds in which the acyl
863 chain varies from two up to 30 carbons, and from zero up to four unsaturations. In
864 addition, no attachments to the acyl chain (such as hydroxylations) were considered. The
865 queries were designed by manually inspecting reference MS/MS spectra of compounds
866 previously synthesized,¹⁴ and we observed that in the vast majority of the cases, the
867 acylium ion—resulting from the stable fatty acid chain fragmentation—was generally
868 absent or present at very low abundances (see **Supplementary Figure 1C**).
869 Consequently, each query was designed to target key MS/MS fragments of the
870 headgroup, in addition to the theoretical precursor ion for each potential *N*-acyl lipid
871 considering the precursor ions as protonated molecules ([M+H]⁺) (**Supplementary**
872 **Figure 1D**). For the compounds for which there were no reference MS/MS libraries, the
873 fragmentation pattern of the heads alone was manually inspected and these patterns
874 were used in addition to the precursor ion inclusion list for each head.

875
876 Once the candidate queries were formulated, their selectivity was initially
877 evaluated by conducting the queries in the GNPS public spectral libraries which contained
878 587,917 spectra of a wide variety of classes of compounds. All job links are available in
879 **Supplementary Table S1**). A false discovery rate (FDR) was estimated by checking the
880 retrieved spectra for each query that matched. We assessed this manually by examining
881 the structures of the spectral matches and determining if they made sense with respect
882 to the expected fragmentation. In cases such as alanine versus sarcosine, which are
883 isomers and have very similar MS/MS spectra, both were accepted as true positives.
884 Matches where the headgroup aligned with the expected fragmentation pattern were
885 considered positive matches, while anything that did not match the headgroup was
886 considered a false positive. Some matches were relative to putative spectra created
887 through the propagation of a molecular network and could match related molecules but
888 be derived from different headgroups (**Supplementary Table S1**).⁸⁴ Therefore, hits
889 against suspect spectra were not considered. If a high FDR was obtained for the GNPS
890 library searches, the query was iteratively refined until the lowest possible FDR was
891 obtained.

892
893 The final queries were then run against publicly available Orbitrap data in
894 GNPS/MassIVE between July and October 2023. (**Supplementary Table S1**). As an
895 additional performance assessment, but now of the repository-scale query results, all of
896 the MS/MS spectra derived from each MassQL query were searched against all publicly
897 available reference spectra in GNPS. The parameters used for the searches were as

898 follows: cosine threshold as above 0.7, minimum matched fragments as 6, and precursor
899 and fragment ion mass tolerance set to 0.02 Da. For almost all queries, the mismatched
900 spectra comprised less than 1% of the spectral matches, except for glycine (FDR 1.5%),
901 which had false positives to ethanolamine conjugates. Some other queries showed an
902 FDR greater than 1%, but these false positives were matches to suspect spectra
903 (**Supplementary Table S1**).⁸⁴

904
905 The queries resulted in the retrieval of a total of 176,732 MS/MS spectra from
906 Orbitrap data in the public domain (**Supplementary Figure 1E**). Six headgroups—
907 selenomethionine, 3-methoxytyrosine, 3-iodothyronamine, levothyroxine (T4),
908 liothyronine (T3), and homocysteine/homocystine—had no candidate *N*-acyl lipid MS/MS
909 matches retrieved. Identical MS/MS spectra obtained from the MassQL queries were
910 merged using MScluster⁸⁵ to reduce duplications, keeping also only the ones that were
911 retrieved at least twice (all GNPS job links are available in **Supplementary Table S1**).
912 This step resulted in 1,474 unique candidate *N*-acyl lipids (**Supplementary Figure 1E**).
913

914 Because some headgroups would result in very few diagnostic ions (e.g., glycine)
915 and could result in spurious matches, an additional filtering step was applied in these
916 results to increase the confidence of the library. This filter was based on cosine similarity
917 calculation between the MS/MS spectra retrieved from the queries and the reference
918 spectra of the compounds previously synthesized.¹⁴ In cases where there were no
919 reference MS/MS spectra available, a modified cosine similarity calculation was
920 performed between the MS/MS retrieved from the query and the reference MS/MS of the
921 headgroup. Therefore, spectra would only pass the filter if the cosine or modified cosine
922 similarity scores would reach values above 0.7. The resulting list of MassQL-filtered
923 spectra represented 851 unique candidate *N*-acyl amides (**Supplementary Table S1**,
924 **Supplementary Figure 1E**), which were used to generate an MS/MS spectral library and
925 leveraged for downstream analyses. This library, named GNPS-N-ACYL-LIPIDS-
926 MASSQL, is currently part of the public GNPS spectral libraries and can be browsed on
927 the web interface at the following link:
928 [https://gnps.ucsd.edu/ProteoSAFe/gnpslibrary.jsp?library=GNPS-N-ACYL-LIPIDS-](https://gnps.ucsd.edu/ProteoSAFe/gnpslibrary.jsp?library=GNPS-N-ACYL-LIPIDS-MASSQL)
929 [MASSQL](https://gnps.ucsd.edu/ProteoSAFe/gnpslibrary.jsp?library=GNPS-N-ACYL-LIPIDS-MASSQL).

930 931 ***N*-acyl lipids repository-scale search**

932 To expand our investigations beyond Orbitrap datasets, we conducted a
933 repository-scale search using a fast MASST (FASST) search,²⁹ an updated and faster
934 version of the Mass Spectrometry Search Tool (MASST),¹⁸ against all the public domain
935 data that were indexed in GNPS.²¹ This search is based on the cosine similarity of the
936 queried spectra against the ones from the public domain in GNPS/MassIVE, regardless
937 of the instrument used for data acquisition. The MGF files generated with MScluster were

938 used as input in the FASST search pipeline, and the parameters used for this search
939 were: cosine similarity above 0.7, minimum matched fragments as 4, and precursor ion
940 and fragment ion tolerances as 0.02 Da. These searches were conducted using the REST
941 web API (<https://zenodo.org/records/7828220>) in October 2023, using *gnps_index*. In
942 addition to getting a table with all the MS/MS spectra matches from the public datasets,
943 outputs from domain-specific MASSTs are also generated with this search: (1)
944 *microbeMASST*: merges the FASST spectral matches against a curated database of
945 more than 60,000 LC-MS/MS files of microbial monocultures that were taxonomically
946 defined;¹⁵ (2) *plantMASST*: merges the FASST matches against 19,075 LC-MS/MS files
947 of plant extracts of taxonomically defined plants;¹⁷ and (3) *foodMASST*: merges FASST
948 matches against ~3,500 LC-MS/MS files of foods and beverages categorized within a
949 food ontology, collected as part of the Global FoodOmics project.^{16,86} These domain-
950 specific MASSTs generated output tables that contain spectral matches to specific data
951 files in the public domain that can be mapped to the curated list of taxonomy/ontology-
952 defined metadata. Therefore, it is possible to map in which microbes, plants, or foods a
953 particular *N*-acyl lipid was previously acquired and deposited in GNPS/MassIVE.

954
955 The FASST search enabled us to retrieve 356,542 MS/MS spectra from 61,833
956 files in 950 datasets and emphasizes how common *N*-acyl lipids are detected in
957 untargeted metabolomics experiments (**Supplementary Table S1**). To explore their
958 distribution in different organisms, tissues, and biofluids, we merged the FASST output
959 with the ReDU (Reanalysis of Data User Interface) controlled vocabulary metadata, which
960 enables us to do comparisons across datasets.¹⁹ This merged table was filtered to contain
961 only rows relative to human ("9606|Homo sapiens") or rodent-related datasets
962 ("10088|Mus", "10090|Mus musculus", "10105|Mus minutoides", "10114|Rattus",
963 "10116|Rattus norvegicus") in the NCBITaxonomy column. Therefore, the total number
964 of unique MS/MS spectra obtained for humans, rodents, microbes, plants, and foods was
965 39,525, 28,497, 29,105, 3,754, and 6,537, respectively (**Supplementary Figure 1E**).

966
967 The FASST searches are performed on indexed spectra, which are MS/MS
968 spectra that are filtered to allow the repository searches to be conducted in seconds. To
969 increase the level of confidence of these matches, an additional cosine similarity was
970 performed on the FASST results to calculate the cosine similarity between the queried
971 spectra and the pre-indexed unfiltered spectra. We filtered these results by removing any
972 MS/MS that resulted in a cosine below 0.7 (**Supplementary Figure 1E**). Therefore, the
973 final numbers based on ReDU and domain-specific MASST analysis were the following:
974 31,299 of the MS/MS spectra could be linked to human samples, 21,866 were found in
975 rodent-related datasets, 22,589 found in microbial monocultures, 2,931 in plant-related
976 data, and 5,576 MS/MS in foods (**Supplementary Figure 1E**).

977

978 The *N*-acyl lipids results obtained from the microbeMASST results were further
979 filtered to: (1) remove any *N*-acyl lipid that was observed in human cell lines (which are
980 also included in microbeMASST as control of host-derived compounds) by filtering
981 outputs in which the taxaname was "Homo sapiens"; (2) remove *N*-acyl lipids that were
982 retrieved only one or two times in the microbeMASST searches; and (3) remove *N*-acyl
983 lipids that appear more than 5% in blanks or QCs (also added in microbeMASST). For
984 the *N*-acyl lipids results of plantMASST, filters (2) and (3) were applied in a similar way.
985 For the foodMASST results, filter (3) only was applied as there are no blanks or QC
986 samples part of foodMASST.

987
988 The results of the queries (**Figure 1B**), body part distributions (**Figure 1C,D**,
989 **Supplementary Figure 2C,D**), and microbeMASST (**Figure 2A,B**) are shown in the form
990 of heatmaps that were created using the "seaborn.clustermap" package (version 0.12.2)
991 in Python (version 3.7.6). The microbial classes were organized in taxonomic order
992 according to NCBI Taxonomy ID. The UpSet plots (**Figure 2C**, **Supplementary Figure**
993 **3A-D**) were generated in R (<https://www.R-project.org/>, version 4.0.0) using the "UpSetR"
994 package (version 1.4.0).⁸⁷ Barplots (**Figure 2B,D**) were created using the
995 "seaborn.barplot" package (version 0.12.2) in Python (version 3.7.6).

996
997 ***Reanalysis of public data from GNPS/MassIVE***

998 The *N*-acyl lipids library created was used to reanalyze several public datasets
999 available in GNPS/MassIVE: (1) a study on monoclonized germ-free mice
1000 ([MSV000088040](https://massive.ucsf.edu/MSV000088040), small intestine and colon samples); (2) a type-1 diabetes study
1001 ([MSV000082261](https://massive.ucsf.edu/MSV000082261), urine samples); (3) a study on body decomposition ([MSV000084322](https://massive.ucsf.edu/MSV000084322)
1002 and [MSV000084463](https://massive.ucsf.edu/MSV000084463), skin and soil samples); and (4) a dataset on the effect of diet and
1003 antibiotics consumption in colorectal cancer ([MSV000080918](https://massive.ucsf.edu/MSV000080918), fecal samples). For each
1004 dataset, the files were downloaded from GNPS/MassIVE and processed in MZmine3
1005 (version 3.9.0).⁸⁸ The parameters used for each study are available in **Supplementary**
1006 **Table S2**, and the MZmine3 batch files are available at
1007 https://github.com/helenamrusso/N-acyl_lipids. The output files generated at the
1008 processing step (.csv file with peak areas and .mgf files with MS/MS information of each
1009 feature) were used as inputs in the Feature-Based Molecular Networking⁸³ workflow in
1010 GNPS2 and wan against the *N*-acyl lipids library.²¹ The parameters of this workflow were
1011 the same for all the datasets, in which the precursor and fragment ions tolerances were
1012 set to 0.02 Da, the minimum matching peak between the queried spectra and the library
1013 was set to 4, a cosine threshold of 0.7 was applied, and no filters considered. The GNPS2
1014 FBMN jobs can be accessed at:

- 1015
1016 • Monoclonized germ-free mice dataset ([MSV000088040](https://massive.ucsf.edu/MSV000088040)):
1017 <https://gnps2.org/status?task=55122ffb51ab4957be51b0073abc8f04>

- 1018
- 1019 • Diabetes dataset ([MSV000082261](#)):
- 1020 <https://gnps2.org/status?task=ed2d2cd94179481d818356271bd7762f>
- 1021
- 1022 • Body decomposition datasets ([MSV000084322](#) and [MSV000084463](#)):
- 1023 <https://gnps2.org/status?task=5f30dc8527bb456190daf2e772bf399d>
- 1024
- 1025 • Impact of diet and antibiotics consumption in colorectal cancer dataset
- 1026 ([MSV000080918](#)):
- 1027 <https://gnps2.org/status?task=ba8fd7da3d654d1d949d4beb398b4152>
- 1028

1029 For the monocolonized germ-free mice, a heatmap was obtained to show the log₂

1030 of the fold change of *N*-acyl lipids levels of colonized and monocolonized mice in relation

1031 to the germ-free group (**Supplementary Figure 3E**). To achieve this, the median of each

1032 feature annotated as an *N*-acyl lipid was calculated and the log₂(FC) was calculated. The

1033 small intestine and colon samples were considered separately. The heatmap was created

1034 using the "seaborn.clustermap" package (version 0.12.2) in Python (version 3.7.6). The

1035 microbial strains were organized in taxonomic order according to NCBI Taxonomy ID and

1036 their classes were also mapped to the heatmap. The *N*-acyl lipids were organized in

1037 ascending order in the number of carbons and unsaturations.

1038

1039 To determine if the *N*-acyl lipid matches had a significant correlation with any of

1040 the groups in each study, the peak areas (exported .csv file from MZmine3) of the

1041 matching compounds in the datasets were plotted as boxplots using the

1042 "seaborn.boxplot" package (version 0.12.2) in Python (version 3.7.6).

1043

1044 Line plots were obtained for the body decomposition dataset to show the changes

1045 in *N*-acyl lipids with increasing body decomposition levels (**Supplementary Figure 3H,I**).

1046 The mean of each feature annotated as an *N*-acyl lipid was calculated for each stage of

1047 decomposition and a line plot was obtained using Matplotlib (version 3.2.1) in Python

1048 (version 3.7.6). Finally, volcano plots were obtained for the diet and antibiotics treatment

1049 study, where the log₂(FC) was calculated for each *N*-acyl lipid (**Figure 2E,F**), and scatter

1050 plots were obtained with Matplotlib (version 3.2.1) in Python (version 3.7.6).

1051

1052 ***Bacterial cultures screening***

1053 ***Bacterial strains, growth conditions, and metabolite extraction***

1054 The bacteria used in this study are listed in the **Supplementary Table S2**. All

1055 bacteria cultures were started from glycerol stock and incubated at 37°C anaerobically

1056 (10% CO₂, 7.5% H₂, 82.5% N₂) in a filtered BHI medium (**Supplementary Table S2**) at a

1057 pH adjusted to 7.2 using 5 N NaOH. Cultures were normalized at OD₆₀₀ = 0.02 before

1058 being diluted 1/10 in 1 mL of mPYG medium (**Supplementary Table S2**) and incubated
1059 for 48-72 h at 37°C in a 2 mL deep-well plate. Following bacterial growth, 400 µL of culture
1060 was transferred to a new 2 mL deep-well plate and extracted overnight at 4°C with 1.2
1061 mL of pre-chilled 50% MeOH/H₂O. Samples were dried in a CentriVap and stored at -
1062 80°C until LC-MS/MS analysis.

1063

1064 ***LC-MS/MS untargeted metabolomics analysis***

1065 Samples were resuspended in 200 µL of 50% MeOH/H₂O with 1 µM of
1066 sulfadimethoxine as internal standard, incubated at -20°C overnight before being
1067 centrifuged at 21,130 x g. Then, 150 µL was transferred into a 2 mL glass vial containing
1068 an insert. The chromatographic separation was performed by reversed-phase polar C18
1069 (Kinetex Polar C18, 100 mm x 2.1 mm, 2.6 µm, 100 Å pore size with a guard column,
1070 Phenomenex) using a Vanquish UHPLC system coupled to a Q-Exactive Orbitrap mass
1071 spectrometer (Thermo Fisher Scientific). The mobile phase consisted of solvent A (water
1072 + 0.1% formic acid) and solvent B (ACN + 0.1% formic acid) and the column compartment
1073 was kept at 40 °C. Five microlitres of the samples were injected and eluted at a flow rate
1074 of 0.5 mL/min using the following gradient: 0 – 1.1 min 5% B, 1.1 – 7.5 min 40% B, 7.5 –
1075 8.5 min 99% B, 8.5 – 9.5 min 99% B, 9.5 – 10 min 5% B, 10 – 10.5 min 5% B, 10.5 –
1076 10.75 min 99% B, 10.75 – 11.25 min 99% B, 11.5 – 12 min 5% B. Mass spectrometry
1077 (MS) analysis was performed using electrospray ionization (ESI) in positive ionization
1078 mode. The parameters were set as follows: Sheath gas flow 53 L/min, auxiliary gas flow
1079 rate 14 L/min, sweep gas flow 3 L/min, spray voltage 3.5 kV, inlet capillary to 269°C, and
1080 auxiliary gas heater set to 438°C. MS scan range 100 – 1000 *m/z* with a resolution ($R_{m/z}$
1081₂₀₀) of 35,000 with 1 microscans. The automatic gain control (AGC) target was set to 1E6
1082 with a maximum injection time of 100 ms. Up to 5 MS/MS spectra per MS1 were collected
1083 with a resolution ($R_{m/z}$ ₂₀₀) set to 17,500 with 1 microscans, maximum injection time of 150
1084 ms with an AGC target of 5E5. The isolation window was set to 1 *m/z* and the isolation
1085 offset at 0 *m/z*. The normalized collision energy was acquired with an increase stepwise
1086 at 25, 40, and 60. The apex trigger was set to 2 – 15 s and a dynamic exclusion of 5 s.
1087 Isotopes were excluded from the analysis. The data is publicly available on
1088 GNPS/MassIVE [MSV000095648](#).

1089

1090 ***Data processing, molecular networking, and data visualization***

1091 The LC-MS/MS files were converted to .mzML using MSConvert (ProteoWizard,
1092 Palo Alto, CA, USA)⁸⁹ and processed in MZmine4 (version 4.0.8).⁸⁸ The parameters used
1093 for data processing are listed in **Supplementary Table S2**. The exported files were
1094 subjected to the FBMN⁸³ workflow in GNPS2.²¹ The parameters used for the library
1095 search for *N*-acyl lipids annotation were as follows: precursor and fragment ion tolerances
1096 set to 0.02 Da, 4 minimum matched peaks between the queried spectra and the library,

1097 a cosine threshold of 0.7, and no filters considered. The GNPS2 FBMN job can be
1098 accessed at <https://gnps2.org/status?task=cff8c1a5895b4b9b917c36ad9444c635>.

1099

1100 A heatmap was obtained to show the variations of the features annotated as *N*-
1101 acyl lipids with regard to the microbial media. A median value was obtained for all the
1102 media samples, and for all the bacteria. A filter was applied to only consider the features
1103 that were detected in both microbial replicates. Therefore, if there were any zero values
1104 for one of the microbial replicates, all values were set to zero. The log₂(FC) was
1105 calculated and plotted using the "seaborn.clustermap" package (version 0.12.2) in Python
1106 (version 3.7.6). The microbial strains were organized in taxonomic order according to
1107 NCBI Taxonomy ID and their classes were also mapped to the heatmap. The *N*-acyl lipids
1108 were organized in ascending order in the number of carbons and unsaturations.

1109

1110 ***Combinatorial reactions of N-acyl lipids***

1111 Fatty acid (1 eq.) and 2 mL of THF were added to a 20 mL scintillation vial with a
1112 magnetic stir bar. To this solution, solid EDC (1 eq.) and neat DIPEA (1 eq.) were
1113 subsequently added, and the solution was stirred at RT. After 15 minutes, amine
1114 compound (1 eq.) in 1mL H₂O was added, and the reaction was stirred for 14 h. To
1115 proceed with LC-MS/MS analyses, 1 µL of the reaction mixture was diluted in 1 mL of LC-
1116 MS grade MeOH.

1117

1118 ***HIV Neurobehavioral Research Center (HNRC) cohort study***

1119 ***Cohort - clinical ratings***

1120 The neurocognitive test battery included measures that assess seven
1121 neurocognitive domains commonly affected by HIV, including verbal fluency, speeded
1122 information processing, executive functions, learning, memory, working memory, and
1123 motor.⁹⁰ Raw scores for each test were converted to demographically corrected T-scores
1124 and used to derive global clinical ratings using a published standardized algorithm that
1125 classifies the presence and severity of NCI. Global ratings have a nine-point scale ranging
1126 from normal (1-4), to mildly impaired (5-6), to moderately or severely impaired (7-9), with
1127 a clinical rating of greater than or equal to 5 indicative of NCI.⁹¹ This is consistent with
1128 Frascati's Criteria for diagnosing HIV-associated neurocognitive disorder, which requires
1129 at least mild neurocognitive impairment in at least two of the seven neurocognitive ability
1130 domains.⁹²

1131

1132 ***Sample preparation***

1133 The study was conducted following protocols approved by the UCSD Human
1134 Research Protections Program (<https://irb.ucsd.edu/>), and all participants gave written
1135 informed consent before participating. Stool samples were processed using a recently
1136 developed automated pipeline designed for simultaneous extraction of metagenomic and

1137 metabolomic data.⁹³ For the metabolites extraction, the swabs were placed into Matrix
1138 Tubes (ThermoFisher Scientific, MA, USA) containing 400 μ L of 95% ethanol (v/v), and
1139 the tubes were sealed using the Capit-All automated capping instrument (ThermoFisher
1140 Scientific, MA, USA). The tubes were shaken at 1,200 rpm for 2 min using a SpexMiniG
1141 plate shaker, followed by centrifugation at 2,700 g for 5 min. Part of the supernatant (200
1142 μ L) was transferred to a deep well plate with an 8-channel pipette, dried down in a vacuum
1143 centrifuge concentrator at room temperature for approximately 5 h, and stored at -80°C
1144 until LC-MS/MS analyses.

1145

1146 ***LC-MS/MS untargeted metabolomics analysis***

1147 Prior to the analyses, the samples were resuspended in 200 μ L of acetonitrile:H₂O
1148 (1:1, v/v) with 100 μ g/L sulfadimethoxine as the internal standard, sonicated for 10 min,
1149 centrifuged at 450 g for 10 min, and 150 μ L of the supernatant was transferred to a
1150 shallow 96 well plate for analyses. The extracts were injected (5 μ L) into a Vanquish
1151 UHPLC system coupled to a Q-Exactive Orbitrap mass spectrometer (Thermo Fisher
1152 Scientific). The chromatographic separation was achieved by reverse-phase polar C18
1153 (150 \times 2.1 mm, 2.6 μ m particle size, 100 A pore size; Phenomenex, Torrance) with a
1154 SecurityGuard C18 column (2.1 mm ID) at 30 $^{\circ}\text{C}$ column temperature. The mobile phase
1155 consisted of solvents A (water) and B (ACN) both containing 0.1% formic acid, and the
1156 flow rate was set at 0.5 mL/min. The following gradient was applied: 0-1 min 5% B, 1-7
1157 min 5-99% B, 7-8 min 99% B, 8-8.5 min 99-5% B, 8-10 min 5%B. Mass spectrometry
1158 (MS) analysis was performed using electrospray ionization (ESI) in positive ionization
1159 mode, and the parameters were set as follows: sheath gas flow 53 L/min, auxiliary gas
1160 flow rate 14 L/min, sweep gas flow 3 L/min, spray voltage 3.5 kV, inlet capillary to 269 $^{\circ}\text{C}$,
1161 and auxiliary gas heater 400 $^{\circ}\text{C}$. MS1 scan range was set to m/z 100-1500 with a
1162 resolution ($R_{m/z\ 200}$) of 35,000, automatic gain control (AGC) target as 5.0E4, and
1163 maximum injection time of 100 ms. Up to 5 MS/MS spectra per MS1 were collected with
1164 a resolution ($R_{m/z\ 200}$) set to 17,500, AGC target as 5.0E4, and maximum injection time of
1165 100 ms. The isolation window was set to 3 m/z and the isolation offset was set to 0.5 m/z .
1166 The normalized collision energy was acquired with an increased stepwise from 20 to 30
1167 to 40%. The apex trigger was set to 2 - 15 s, the minimum AGC target for the MS/MS
1168 spectrum was 5.0E3, and a dynamic precursor exclusion of 10 s was selected. This
1169 dataset is publicly available in GNPS/MassIVE under the following accession number:

1170

1171 ***Data processing and Feature-Based Molecular Networking***

1172 The LC-MS/MS files were converted to .mzML using MSConvert (ProteoWizard,
1173 Palo Alto, CA, USA)⁸⁹ and processed in MZmine3 (version 3.9.0).⁸⁸ The parameters used
1174 for data processing are listed in **Supplementary Table S2**. The exported files were
1175 subjected to the FBMN⁸³ workflow in GNPS2.²¹ No filters were applied to the data, and
1176 the precursor and MS/MS fragment ion tolerances were set to 0.02 Da. A molecular

1177 network was created, in which the edges were filtered to have a cosine score above 0.7
1178 and at least four matched fragments. Similarly, the parameters for the *N*-acyl lipids library
1179 search were set to have a cosine value above 0.7 and at least four matched fragments.
1180 The GNPS2 FBMN job can be accessed at
1181 <https://gnps2.org/status?task=ee34ee95908749dd81ee9a62fbdac98e>. The molecular
1182 networks were visualized in Cytoscape⁹⁴ (version 3.10.0).

1183

1184 ***Metagenomic data sequencing***

1185 Fecal samples were processed for shotgun metagenomics sequencing as
1186 previously described.⁹⁵ The metagenomic libraries were normalized by iSeq (Illumina)
1187 read count distribution to generate a final pool that made sequencing on the NovaSeq
1188 more efficient.⁹⁶ Raw sequence files were demultiplexed using BaseSpace (Illumina, CA,
1189 USA), and quality-filtered following a previous protocol.⁹⁷ The filtered reads were aligned
1190 to the Web of Life database⁹⁸ using bowtie2,⁹⁹ and the settings used were the following:
1191 maximum and minimum mismatch penalties (mp=[1,1]), a penalty for ambiguities (np=1;
1192 default), read and reference gap open- and extend penalties (rdg=[0,1], rfg=[0,1]), a
1193 minimum alignment score for an alignment to be considered valid (score-min=[L,0,-0.05]),
1194 a defined number of distinct, valid alignments (k=16), and the suppression of SAM records
1195 for unaligned reads, as well as SAM headers (no-unal, no-hd). A feature table was
1196 obtained by converting the resulting alignments using the Web of Life Toolkit App.¹⁰⁰

1197

1198 ***Metagenomic data processing***

1199 The metagenomic data processing was performed as previously described.¹⁰¹ The
1200 sequence data were filtered for all adapters known to fastp (version 0.23.4) in paired-end
1201 mode by explicitly specifying a known adapters file.¹⁰² Fastp also removed sequences
1202 shorter than 45 nucleotides with -l, a flag to filter the minimum length of each sequence.
1203 Each sample was then filtered against each genome in the human pangenome,¹⁰³ as well
1204 as both T2T-CHM13v2.0¹⁰⁴ and GRCh38,¹⁰⁵ using minimap2¹⁰⁶ (version 2.26-r1175) with
1205 “-ax sr” for short read mode. The data were first run in paired-end mode, and then run in
1206 single-end mode, per genome. Each successive run was converted from SAM to FASTQ
1207 using samtools¹⁰⁷ (version 1.17) with arguments -f 12 -F 256 -N for paired-end data and
1208 -f 4 -F 256 for single-end. The single-end data are repaired using fastq_pair¹⁰⁸ (version
1209 1.0) specifying a table size of 50M with -t. Compute support was provided with GNU
1210 Parallel¹⁰⁹ (version 20180222). Single-end FASTQ output from samtools was split into R1
1211 and R2 with a custom Rust program, with rust-bio for parsing¹¹⁰ (version 1.4.0). Data were
1212 multiplexed with sed and demultiplexed using a custom Python script. Shotgun
1213 sequencing data were then uploaded to and processed through Qiita¹¹¹ (Study ID 11135).
1214 Sequence adapter and host filtering were executed using qp-fastp-minimap2 version
1215 2022.04. Subsequently, Woltka¹⁰⁰ version 0.1.4 (qp-woltka 2022.09) with the Web of Life
1216 2 database was employed for taxonomic and functional predictions. Genomic coverages

1217 were computed, and features with less than 25% coverage were excluded.¹¹² To further
1218 enhance data quality, a prevalence filter using QIIME 2 v2023.5¹¹³ was applied,
1219 eliminating features present in less than 10% of samples to mitigate the inclusion of
1220 erroneous and low-quality reads. The resulting feature table was utilized for downstream
1221 analysis.

1222

1223 ***Microbe-metabolite multi-omics associations***

1224 Co-occurrence probabilities between microbes and metabolites were calculated
1225 using mmvec⁴⁰ (version 1.0.4) as a Qiime2¹¹³ plugin. Mmvec takes as input the relative
1226 abundance matrix for the sequencing data and the feature abundance table for the ion
1227 features, and through a neural networking approach, conditional probabilities of observing
1228 molecules based on the abundance of each microbe are calculated. A subset of samples
1229 with both metabolite and microbiome data were used for this analysis (225 samples). The
1230 mmvec parameters were as follows: -p-batch-size 50, -p-num-testing-examples 5, -p-
1231 epochs 50, -p-learning-rate 1e-4. All other parameters for the analyses were set as the
1232 default values. EMPeror¹¹⁴ was used to visually inspect the feature-feature biplots
1233 (<https://view.qiime2.org/>). The spheres on the plot were colored based on which group
1234 (HIV+ vs HIV-) the molecules were most abundant, and the arrows indicate the 30 most
1235 important OTUs retrieved from the analyses (*i.e.*, higher magnitude of the vector using
1236 Euclidean distance from the origin) (**Figure 3D**). The co-occurrence probabilities were
1237 also inspected at the microbial order taxonomic level for the histamine and cadaverine *N*-
1238 acyl lipids. Only histamine-C2:0 and histamine-C3:0 had co-occurrence probabilities >
1239 6.0, and a network was obtained for the microbial orders that were shared between both
1240 compounds (**Figure 3E**). The network was visualized in Cytoscape⁹⁴ (version 3.10.0). All
1241 inputs and outputs from mmvec and the Cytoscape visualization file are available at
1242 https://github.com/helenamrusso/N-acyl_lipids.

1243

1244 ***Microbial cultures from the multi-omics analysis***

1245 *Holdemanella biformis* DSM 3989, *Catenibacterium mitsuokai* DSM 15897,
1246 *Megasphaera* sp. DSMZ 102144, *Dorea longicatena* DSM 13814, *Prevotella buccae* D17,
1247 *Eubacterium siraeum* DSM 15702, *Collinsella aerofaciens* ATCC 25986, *Roseburia*
1248 *inulinivorans* DSM 16841, and *Streptococcus thermophilus* LMD-9 were selected for
1249 microbial culturing based on the multi-omics results and strains availability. these
1250 microbes were cultured in 200 µL in BHI medium (**Supplementary Table S2**) for 72 h at
1251 37°C in an anaerobic chamber supplemented with 100 µM of cadaverine, putrescine, and
1252 histamine. Samples were extracted overnight at 4°C using 600 µL of pre-chilled 50%
1253 MeOH/H₂O. Samples were then dried using a CentriVap and stored at -80°C until
1254 resuspension.

1255

1256 ***Untargeted LC-MS/MS analysis of microbes from the multi-omics HIV***

1257 **analysis**

1258 The microbial extracts were resuspended in H₂O (100%) containing 1 μM of
1259 sulfamethazine to achieve a concentration of 50 mg/mL, incubated at -20°C overnight,
1260 and centrifuged at 21,130 x g. Then, 120 μL of the solution was transferred to a 2 mL
1261 glass vial containing an insert for LC-MS/MS analysis. The samples were injected (2 μL)
1262 into a Vanquish UHPLC system coupled to a Q-Exactive Orbitrap mass spectrometer
1263 (Thermo Fisher Scientific). The chromatographic separation was achieved by reverse-
1264 phase polar C18 (Kinetex Polar C18, 100 × 2.1 mm, 2.6 μm particle size, 100 Å pore size;
1265 Phenomenex, Torrance) with a SecurityGuard C18 column (2.1 mm ID) at 40 °C column
1266 temperature. The mobile phase consisted of solvents A (water) and B (ACN) both
1267 containing 0.1% formic acid, and the flow rate was set at 0.5 mL/min. The gradient
1268 employed consisted of 0-1 min 1% B, 1-7.5 min 5-99% B, 7.5-9.3 min 99% B, 9.3-9.5 min
1269 99-1% B, 9.5-11 min 1%B. Mass spectrometry (MS) analysis was performed using
1270 electrospray ionization (ESI) in positive ionization mode, and the parameters were set as
1271 follows: sheath gas flow 53 L/min, auxiliary gas flow rate 14 L/min, sweep gas flow 3
1272 L/min, spray voltage 3.5 kV, inlet capillary to 269°C, and auxiliary gas heater 430 °C. MS1
1273 scan range was set to *m/z* 100-1500 with a resolution ($R_{m/z\ 200}$) of 35,000, automatic gain
1274 control (AGC) target as 5.0E4, and maximum injection time of 100 ms. Up to 5 MS/MS
1275 spectra per MS1 were collected with a resolution ($R_{m/z\ 200}$) set to 17,500, AGC target as
1276 5.0E5, and maximum injection time of 50 ms. The isolation window was set to 2 *m/z* and
1277 the isolation offset was set to 0 *m/z*. The normalized collision energy was acquired with
1278 an increased stepwise from 25 to 40 to 60%. The apex trigger was set to 1 to 5 s, the
1279 minimum AGC target for the MS/MS spectrum was 8.0E3, and a dynamic precursor
1280 exclusion of 10 s was selected. The data was deposited in GNPS/MassIVE and is publicly
1281 available at [MSV000095648](#).

1282
1283 **Retention time and MS/MS matching with combinatorial synthetic standard**
1284 **reaction mixtures**

1285 Extracts from skin samples of the body decomposition study ([MSV000084322](#)) and
1286 the HIV study ([MSV000092833](#)) were available in our laboratory for additional analyses
1287 to get retention time and MS/MS spectral matching between synthetic standards and
1288 biological samples. In addition, the samples from the microbial monocultures described
1289 in the "*Bacterial cultures screening*" section were used to confirm the microbial production
1290 of selected *N*-acyl lipids. Therefore, the biological samples and the synthetic standards
1291 were subjected to LC-MS/MS analyses. The dried extracts were resuspended in 150 μL
1292 of MeOH:H₂O (1:1, v/v) for the microbial extracts (n = 2) and the body decomposition
1293 samples (n = 4), while the HIV samples (n = 4) were resuspended in 150 μL of H₂O
1294 (100%). The same method described in "*Untargeted LC-MS/MS analysis of microbes*
1295 *from the multi-omics HIV analysis*" was used to acquire the data. However, two different
1296 gradients were used to evaluate the retention time matching between the synthetic *N*-acyl

1297 lipids and the compounds present in the biological samples: the first gradient (LC1)
1298 consisted of 0-1 min 1% B, 1-7.5 min 5-99% B, 7.5-9.3 min 99% B, 9.3-9.5 min 99-1% B,
1299 9.5-11 min 1%B; and the second gradient (LC2) consisted of 0-1.5 min 1% B, 1.5-10.5
1300 min 5-99% B, 10.5-12.3 min 99% B, 12.3-12.5 min 99-1% B, 12.5-14 min 1%B. The
1301 acquired LC-MS/MS data was deposited in GNPS/MassIVE and is publicly available at
1302 [MSV000095423](#).

1303

1304 **Obtention of pure *N*-acyl lipids**

1305 Pure *N*-acyl lipids were acquired commercially from Sigma-Aldrich, Aldlab
1306 Chemicals, or EnamineStore. More specifically, *N*-(2-(1H-imidazol-4-yl)ethyl)acetamide
1307 (histamine-C2:0, purity 98%), *N*-(5-aminopentyl)acetamide (cadaverine-C2:0, purity
1308 95%), *N*-(3,4-dihydroxyphenethyl)acetamide (dopamine-C2:0, purity 95%), and *N*-(2-(5-
1309 hydroxy-1H-indol-3-yl)ethyl)acetamide (serotonin-C2:0, purity >99%) were acquired from
1310 Sigma-Aldrich; *N*-(2-(1H-imidazol-4-yl)ethyl)propionamide (histamine-C3:0, purity 98%),
1311 *N*-(2-(1H-imidazol-4-yl)ethyl)butyramide (histamine-C4:0, purity 95%), *N*-(2-(1H-
1312 imidazol-4-yl)ethyl)pentanamide (histamine-C5:0, purity 98%), and *N*-(5-
1313 aminopentyl)propionamide (cadaverine-C3:0, purity 95%) were acquired from
1314 EnamineStore; and *N*-(2-(1H-imidazol-4-yl)ethyl)hexanamide (histamine-C6:0, purity
1315 95%), *N*-(5-aminopentyl)pentanamide (cadaverine-C5:0, purity 95%), *N*-(5-
1316 aminopentyl)hexanamide (cadaverine-C6:0, purity 95%), *N*-(5-aminopentyl)heptanamide
1317 (cadaverine-C7:0, purity 95%), and propionyl-L-tryptophan (tryptophan-C3:0, purity 95%)
1318 were acquired from Aldlab Chemicals.

1319 The structure of these *N*-acyl lipids was confirmed by NMR ¹H. NMR spectra were
1320 collected at 298 K on a 600 MHz Bruker Avance III spectrometer fitted with a 1.7 mm
1321 triple resonance cryoprobe with z-axis gradients. The spectra were acquired in CD₃OD-
1322 *d*₄ or CDCl₃-*d*₁, which was chosen based on the solubility of the compounds. The shifts
1323 are reported in ppm and calibrated against the residual solvent signals at δ_H 3.31 and
1324 7.26 for CD₃OD-*d*₄ and CDCl₃-*d*₁ respectively. The deuterated solvents were acquired
1325 from Cambridge Isotope Laboratories, Inc. (Andover, USA). The NMR data acquired were
1326 deposited in Zenodo (<https://doi.org/10.5281/zenodo.14015081>).

1327

1328 **Quantification of *N*-acyl lipids in biological samples**

1329 The LC-MS/MS method used for the analyses of the method validation and
1330 quantification was the same as previously described in the "*Retention time and MS/MS*
1331 *matching with combinatorial synthetic standard reaction mixtures*" section, employing
1332 gradient LC1. The analytical method was performed according to the International
1333 Conference on Harmonization (ICH) guidelines¹¹⁵ for histamine-C2:0, histamine-C3:0,
1334 histamine-C4:0, histamine-C5:0, cadaverine-C2:0, cadaverine-C3:0, cadaverine-C5:0,
1335 cadaverine-C6:0, and dopamine-C2:0. The method was validated based on the
1336 evaluation of the following parameters: specificity, precision (repeatability and

1337 intermediate precision), linearity, limit of detection (LOD), limit of quantification (LOQ),
1338 and accuracy. Detailed information regarding the methodology used for each of them is
1339 described below, and all the figures of merit are available in **Supplementary Table S3**.
1340 The validation was performed using sample P3_D9_Sample_X3157299 from the HNRC
1341 cohort that would contain the compounds of interest. Skyline¹¹⁶ (version 23.1) was used
1342 to extract the peak areas of the *N*-acyl lipids. The method employed reached the
1343 acceptance criteria specified for each parameter (**Supplementary Table S3**). For
1344 quantification in biological samples, 148 samples of the HIV cohort were available and
1345 injected in the validated method (samples were resuspended in 100 μ L of H₂O
1346 containing 1 μ M of sulfamethazine). For the calculation of the amounts in the samples, it
1347 was estimated that 10 mg of stool sample would be the starting material, as previously
1348 described,¹¹⁷ and the extraction yield was also extrapolated to 100%. In addition, all the
1349 samples of the microbial monocultures described in the "*Microbial cultures from the*
1350 *multi-omics analysis*" were also analyzed. The injection volume was set to 2 μ L for all
1351 samples.

1352

1353 **Specificity**

1354 The specificity was determined by injecting a blank solution containing only the
1355 internal standard (sulfadimethazine), and an injection of a solution containing all the *N*-
1356 acyl lipids (n=3). The relative standard deviation (RSD) was calculated based on each
1357 peak's retention time in the P3_D9_Sample_X3157299 sample. The MS and MS/MS
1358 spectra confirmed the specificity and identity of these compounds. The retention times of
1359 the peaks of interest were as follows: histamine-C2:0, 0.58 min; histamine-C3:0, 0.73 min;
1360 histamine-C4:0, 1.13 min; histamine-C5:0, 2.29 min; cadaverine-C2:0, 0.61 min;
1361 cadaverine-C3:0, 0.78 min; cadaverine-C5:0, 2.47 min; cadaverine-C6:0, 2.94 min;
1362 dopamine-C2:0, 2.60 min. These compounds didn't show interferences compared to the
1363 solution containing only the mixture of standards.

1364

1365 **Precision (repeatability and intermediate precision)**

1366 The precision of the method was determined by analyzing the
1367 P3_D9_Sample_X3157299 sample in six replicates (n=6), and the repeatability (intra-day
1368 precision) was estimated as the RSD of the standards concentrations (μ g/mL) measured
1369 in two consecutive days. The concentrations calculated for the compounds on both days
1370 are available in **Supplementary Table S3**. The RSD values were lower than 5%, and the
1371 F-test between the two days showed no significant difference at F=0.05.

1372

1373 **Linearity**

1374 The linearity of the method was determined by calibration curves in concentration
1375 ranges comprising each compound at the samples of interest. A stock solution containing
1376 60 μ g/mL of each *N*-acyl lipid was prepared in H₂O (100%) and used to acquire calibration

1377 curves for all the compounds simultaneously. From this solution, 6 to 13 points were
1378 prepared with levels ranging from 0.001 to 20 µg/mL, and each concentration level was
1379 injected in triplicate. The analytical curves were built based on the nominal
1380 concentrations, and the average between the ratios of each compound and the internal
1381 standard used ($\text{Ratio} = A_{\text{compound}}/A_{\text{IS}}$). A polynomial equation was obtained for each curve,
1382 and the correlation coefficients (R) were calculated for each compound. The linear ranges
1383 and R coefficients are available in **Supplementary Table S3**.

1384

1385 ***Limit of detection and limit of quantification***

1386 LODs and LOQs were estimated by the mean of the slopes (a) and the standard
1387 deviation of the y-intercept (Sb) on three calibration curves (linear regression was used)
1388 in three low concentrations for each compound (0.002 to 0.02 µg/mL). A linear regression
1389 was used in this estimation. These limits were calculated by the following equations: $\text{LOD} = (3.3 \cdot \text{Sb})/a$ and $\text{LOQ} = (10 \cdot \text{Sb})/a$. All the slopes, intercepts, LODs, and LOQs are shown
1390 in **Supplementary Table S3**.

1391

1392 ***Accuracy***

1394 The accuracy of the method was determined by recovery analyses. For this, known
1395 amounts of the solution containing the standards were spiked to the
1396 P3_E10_Sample_x3137731 and P3_G2_Sample_X3148765 sample solutions in two
1397 different concentrations (low and high) considering the predetermined calibration curve
1398 and concentration range. Three replicates for each level were injected and analyzed in
1399 the validated method. The accuracy was determined by the difference between the
1400 theoretical and experimental concentration values and the values were within the
1401 acceptance range of 80–120%.

1402

1403 ***Statistical analyses***

1404 Statistical tests were performed using the non-parametric Mann-Whitney U test in
1405 cases where two groups were being compared (diabetes, diet, and antibiotic treatment -
1406 **Supplementary Figure 3G,L,M, Figure 2E,F**), or with the non-parametric Kruskal-Wallis
1407 for more than two groups (body decomposition - **Supplementary Figure 3J,K**). The p-
1408 values were corrected for multiple comparisons using the Benjamini-Hochberg correction.
1409 The statistical tests were done with the "scipy.stats" package (version 1.7.3), and the p-
1410 values corrections with the "statsmodels.stats.multitest" (version 0.11.1) in Python
1411 (version 3.7.6).

1412

1413 For the HNRC study, the differences in individual N-acyl lipids between the study
1414 groups were compared using a multivariate linear mixed-effects model with fixed
1415 covariates for HIV status (PWH vs. PWOH) and neurocognitive impairment status
1416 (impaired vs. unimpaired) (~ HIV status + neurocognitive impairment), while accounting

1417 for random effects within individual samples (~1 | Subject) using the MaAsLin2 package
1418 in R (version 4.2.1). Lipid values were log-transformed, and zero values were imputed
1419 with half the minimum value prior to analysis. The regression coefficients from the linear
1420 model were illustrated as a forest plot using the 'ggplot2' (version 3.5.1) package in R
1421 (version 4.2.1). To visualize the correlation coefficients from the linear model with only
1422 fixed effects (i.e., the association between CD4/CD8 ratio or plasma viral load), a
1423 horizontal bar plot was created using 'ggplot2' (version 3.5.1). The color palettes were
1424 selected from the RColorBrewer(version 1.1.3) package in R (version 4.2.1).

1425

1426 **Supplementary table titles and legends:**

1427

1428 **Supplementary Table S1.** Queries jobs, queries results, and body part distribution for
1429 rodents and humans, related do Figure 1.

1430

1431 **Supplementary Table S2.** *N*-acyl lipids chain length diversity, evidence of microbial *N*-
1432 acyl lipids, and reanalysis of public datasets, related to Figure 2.

1433

1434 **Supplementary Table S3.** HIV and neurocognition study, multiomics results and
1435 quantification of *N*-acyl lipids, related to Figure 3.

1436

1437 **Supplementary Table S4.** Microbial production and activity data of *N*-acyl lipids, related
1438 to Figure 4.

1439

1440

1441 **References**

- 1442 1. Chang, F.-Y., Siuti, P., Laurent, S., Williams, T., Glassey, E., Sailer, A.W., Gordon,
1443 D.B., Hemmerle, H., and Voigt, C.A. (2021). Gut-inhabiting Clostridia build human
1444 GPCR ligands by conjugating neurotransmitters with diet- and human-derived fatty
1445 acids. *Nat Microbiol* 6, 792–805.
- 1446 2. Mann, A., Smoum, R., Trembovler, V., Alexandrovich, A., Breuer, A., Mechoulam,
1447 R., and Shohami, E. (2015). Palmitoyl Serine: An Endogenous Neuroprotective
1448 Endocannabinoid-Like Entity After Traumatic Brain Injury. *J. Neuroimmune*
1449 *Pharmacol.* 10, 356–363.
- 1450 3. Waluk, D.P., Vielfort, K., Derakhshan, S., Aro, H., and Hunt, M.C. (2013). *N*-Acyl
1451 taurines trigger insulin secretion by increasing calcium flux in pancreatic β -cells.
1452 *Biochem. Biophys. Res. Commun.* 430, 54–59.
- 1453 4. Aichler, M., Borgmann, D., Krumsiek, J., Buck, A., MacDonald, P.E., Fox, J.E.M.,
1454 Lyon, J., Light, P.E., Keipert, S., Jastroch, M., et al. (2017). *N*-acyl Taurines and
1455 Acylcarnitines Cause an Imbalance in Insulin Synthesis and Secretion Provoking β

- 1456 Cell Dysfunction in Type 2 Diabetes. *Cell Metab.* 25, 1334–1347.e4.
- 1457 5. Arul Prakash, S., and Kamlekar, R.K. (2021). Function and therapeutic potential of
1458 N-acyl amino acids. *Chem. Phys. Lipids* 239, 105114.
- 1459 6. Long, J.Z., Svensson, K.J., Bateman, L.A., Lin, H., Kamenecka, T., Lokurkar, I.A.,
1460 Lou, J., Rao, R.R., Chang, M.R., Jedrychowski, M.P., et al. (2016). The secreted
1461 enzyme PM20D1 regulates lipidated amino acid uncouplers of mitochondria. *Cell*
1462 166, 424–435.
- 1463 7. Connor, M., Vaughan, C.W., and Vandenberg, R.J. (2010). N-acyl amino acids and
1464 N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug
1465 targets. *Br. J. Pharmacol.* 160, 1857–1871.
- 1466 8. Jörgensen, A.M., Wibel, R., and Bernkop-Schnürch, A. (2023). Biodegradable
1467 cationic and ionizable cationic lipids: A roadmap for safer pharmaceutical
1468 excipients. *Small* 19, e2206968.
- 1469 9. Mokhtari, V., Afsharian, P., Shahhoseini, M., Kalantar, S.M., and Moini, A. (2017).
1470 A review on various uses of N-acetyl cysteine. *Cell J.* 19, 11–17.
- 1471 10. Conroy, M.J., Andrews, R.M., Andrews, S., Cockayne, L., Dennis, E.A., Fahy, E.,
1472 Gaud, C., Griffiths, W.J., Jukes, G., Kolchin, M., et al. (2024). LIPID MAPS: update
1473 to databases and tools for the lipidomics community. *Nucleic Acids Res.* 52,
1474 D1677–D1682.
- 1475 11. Xue, J., Chi, L., Tu, P., Lai, Y., Liu, C.-W., Ru, H., and Lu, K. (2021). Detection of
1476 gut microbiota and pathogen produced N-acyl homoserine in host circulation and
1477 tissues. *NPJ Biofilms Microbiomes* 7, 53.
- 1478 12. Tan, B., O'Dell, D.K., Yu, Y.W., Monn, M.F., Hughes, H.V., Burstein, S., and
1479 Walker, J.M. (2010). Identification of endogenous acyl amino acids based on a
1480 targeted lipidomics approach. *J. Lipid Res.* 51, 112–119.
- 1481 13. Wood, P.L. (2019). Targeted lipidomics and metabolomics evaluations of cortical
1482 neuronal stress in schizophrenia. *Schizophr. Res.* 212, 107–112.
- 1483 14. Gentry, E.C., Collins, S.L., Panitchpakdi, M., Belda-Ferre, P., Stewart, A.K., Carrillo
1484 Terrazas, M., Lu, H.-H., Zuffa, S., Yan, T., Avila-Pacheco, J., et al. (2023). Reverse
1485 metabolomics for the discovery of chemical structures from humans. *Nature*.
1486 <https://doi.org/10.1038/s41586-023-06906-8>.
- 1487 15. Zuffa, S., Schmid, R., Bauermeister, A., P Gomes, P.W., Caraballo-Rodriguez,
1488 A.M., El Abiead, Y., Aron, A.T., Gentry, E.C., Zemlin, J., Meehan, M.J., et al.
1489 (2024). microbeMASST: a taxonomically informed mass spectrometry search tool
1490 for microbial metabolomics data. *Nat Microbiol* 9, 336–345.
- 1491 16. West, K.A., Schmid, R., Gauglitz, J.M., Wang, M., and Dorrestein, P.C. (2022).
1492 foodMASST a mass spectrometry search tool for foods and beverages. *NPJ Sci*
1493 *Food* 6, 22.
- 1494 17. Gomes, P.W.P., Mannocho-Russo, H., Schmid, R., Zuffa, S., Damiani, T., Quiros-
1495 Guerrero, L.-M., Caraballo-Rodríguez, A.M., Zhao, H.N., Yang, H., Xing, S., et al.

- 1496 (2024). plantMASST - Community-driven chemotaxonomic digitization of plants.
1497 bioRxiv. <https://doi.org/10.1101/2024.05.13.593988>.
- 1498 18. Wang, M., Jarmusch, A.K., Vargas, F., Aksenov, A.A., Gauglitz, J.M., Weldon, K.,
1499 Petras, D., da Silva, R., Quinn, R., Melnik, A.V., et al. (2020). Mass spectrometry
1500 searches using MASST. *Nat. Biotechnol.* *38*, 23–26.
- 1501 19. Jarmusch, A.K., Wang, M., Aceves, C.M., Advani, R.S., Aguirre, S., Aksenov, A.A.,
1502 Aleti, G., Aron, A.T., Bauermeister, A., Bolleddu, S., et al. (2020). ReDU: a
1503 framework to find and reanalyze public mass spectrometry data. *Nat. Methods* *17*,
1504 901–904.
- 1505 20. Jarmusch, A.K., Aron, A.T., Petras, D., Phelan, V.V., Bittremieux, W., Acharya,
1506 D.D., Ahmed, M.M.A., Bauermeister, A., Bertin, M.J., Boudreau, P.D., et al. (2022).
1507 A Universal Language for Finding Mass Spectrometry Data Patterns. bioRxiv,
1508 2022.08.06.503000. <https://doi.org/10.1101/2022.08.06.503000>.
- 1509 21. Wang, M., Carver, J.J., Phelan, V.V., Sanchez, L.M., Garg, N., Peng, Y., Nguyen,
1510 D.D., Watrous, J., Kapon, C.A., Luzzatto-Knaan, T., et al. (2016). Sharing and
1511 community curation of mass spectrometry data with Global Natural Products Social
1512 Molecular Networking. *Nat. Biotechnol.* *34*, 828–837.
- 1513 22. Mohanty, I., Mannocho-Russo, H., Schweer, J.V., El Abiead, Y., Bittremieux, W.,
1514 Xing, S., Schmid, R., Zuffa, S., Vasquez, F., Muti, V.B., et al. (2024). The
1515 underappreciated diversity of bile acid modifications. *Cell* *187*, 1801–1818.e20.
- 1516 23. Watanabe, K., Yasugi, E., and Oshima, M. (2000). How to search the glycolipid
1517 data in “LIPIDBANK for web” the newly developed lipid database in japan. *Trends*
1518 *Glycosci. Glycotechnol.* *12*, 175–184.
- 1519 24. Aimo, L., Liechti, R., Hyka-Nouspikel, N., Niknejad, A., Gleizes, A., Götz, L.,
1520 Kuznetsov, D., David, F.P.A., van der Goot, F.G., Riezman, H., et al. (2015). The
1521 SwissLipids knowledgebase for lipid biology. *Bioinformatics* *31*, 2860–2866.
- 1522 25. Bhandari, S., Bisht, K.S., and Merkler, D.J. (2021). The Biosynthesis and
1523 Metabolism of the N-Acylated Aromatic Amino Acids: N-Acylphenylalanine, N-
1524 Acyltyrosine, N-Acyltryptophan, and N-Acylhistidine. *Front Mol Biosci* *8*, 801749.
- 1525 26. Ghosh, A.K., and Shahabi, D. (2021). Synthesis of amide derivatives for electron
1526 deficient amines and functionalized carboxylic acids using EDC and DMAP and a
1527 catalytic amount of HOBt as the coupling reagents. *Tetrahedron Lett.* *63*.
1528 <https://doi.org/10.1016/j.tetlet.2020.152719>.
- 1529 27. Sumner, L.W., Amberg, A., Barrett, D., Beale, M.H., Beger, R., Daykin, C.A., Fan,
1530 T.W.-M., Fiehn, O., Goodacre, R., Griffin, J.L., et al. (2007). Proposed minimum
1531 reporting standards for chemical analysis Chemical Analysis Working Group
1532 (CAWG) Metabolomics Standards Initiative (MSI). *Metabolomics* *3*, 211–221.
- 1533 28. Schymanski, E.L., Jeon, J., Gulde, R., Fenner, K., Ruff, M., Singer, H.P., and
1534 Hollender, J. (2014). Identifying small molecules via high resolution mass
1535 spectrometry: communicating confidence. *Environ. Sci. Technol.* *48*, 2097–2098.

- 1536 29. Batsoyol, N., Pullman, B., Wang, M., Bandeira, N., and Swanson, S. (2022). P-
1537 Massive: A Real-Time Search Engine for a Multi-Terabyte Mass Spectrometry
1538 Database. In SC22: International Conference for High Performance Computing,
1539 Networking, Storage and Analysis, pp. 1–15.
- 1540 30. Shalapour, S., Lin, X.-J., Bastian, I.N., Brain, J., Burt, A.D., Aksenov, A.A.,
1541 Vrbanac, A.F., Li, W., Perkins, A., Matsutani, T., et al. (2017). Inflammation-induced
1542 IgA+ cells dismantle anti-liver cancer immunity. *Nature* 551, 340–345.
- 1543 31. Song, X., Zhang, H., Zhang, Y., Goh, B., Bao, B., Mello, S.S., Sun, X., Zheng, W.,
1544 Gazzaniga, F.S., Wu, M., et al. (2023). Gut microbial fatty acid isomerization
1545 modulates intraepithelial T cells. *Nature* 619, 837–843.
- 1546 32. Wu, M., Zheng, W., Song, X., Bao, B., Wang, Y., Ramanan, D., Yang, D., Liu, R.,
1547 Macbeth, J.C., Do, E.A., et al. (2024). Gut complement induced by the microbiota
1548 combats pathogens and spares commensals. *Cell* 187, 897–913.e18.
- 1549 33. Cheng, J., Venkatesh, S., Ke, K., Barratt, M.J., and Gordon, J.I. (2024). A human
1550 gut *Faecalibacterium prausnitzii* fatty acid amide hydrolase. *Science* 386.
1551 <https://doi.org/10.1126/science.ado6828>.
- 1552 34. Cheng, A.G., Ho, P.-Y., Aranda-Díaz, A., Jain, S., Yu, F.B., Meng, X., Wang, M.,
1553 Iakiviak, M., Nagashima, K., Zhao, A., et al. (2022). Design, construction, and in
1554 vivo augmentation of a complex gut microbiome. *Cell* 185, 3617–3636.e19.
- 1555 35. Burcham, Z.M., Belk, A.D., McGivern, B.B., Bouslimani, A., Ghadermazi, P.,
1556 Martino, C., Shenhav, L., Zhang, A.R., Shi, P., Emmons, A., et al. (2024). A
1557 conserved interdomain microbial network underpins cadaver decomposition despite
1558 environmental variables. *Nat Microbiol* 9, 595–613.
- 1559 36. Watrous, J., Roach, P., Alexandrov, T., Heath, B.S., Yang, J.Y., Kersten, R.D., van
1560 der Voort, M., Pogliano, K., Gross, H., Raaijmakers, J.M., et al. (2012). Mass
1561 spectral molecular networking of living microbial colonies. *Proc. Natl. Acad. Sci. U.*
1562 *S. A.* 109, E1743–E1752.
- 1563 37. Quinn, R.A., Melnik, A.V., Vrbanac, A., Fu, T., Patras, K.A., Christy, M.P., Bodai,
1564 Z., Belda-Ferre, P., Tripathi, A., Chung, L.K., et al. (2020). Global chemical effects
1565 of the microbiome include new bile-acid conjugations. *Nature* 579, 123–129.
- 1566 38. Quinn, R.A., Nothias, L.-F., Vining, O., Meehan, M., Esquenazi, E., and Dorrestein,
1567 P.C. (2017). Molecular networking as a drug discovery, drug metabolism, and
1568 precision medicine strategy. *Trends Pharmacol. Sci.* 38, 143–154.
- 1569 39. Buggert, M., Frederiksen, J., Noyan, K., Svärd, J., Barqasho, B., Sönnnerborg, A.,
1570 Lund, O., Nowak, P., and Karlsson, A.C. (2014). Multiparametric bioinformatics
1571 distinguish the CD4/CD8 ratio as a suitable laboratory predictor of combined T cell
1572 pathogenesis in HIV infection. *J. Immunol.* 192, 2099–2108.
- 1573 40. Morton, J.T., Aksenov, A.A., Nothias, L.F., Foulds, J.R., Quinn, R.A., Badri, M.H.,
1574 Swenson, T.L., Van Goethem, M.W., Northen, T.R., Vazquez-Baeza, Y., et al.
1575 (2019). Learning representations of microbe-metabolite interactions. *Nat. Methods*

- 1576 16, 1306–1314.
- 1577 41. Mann, E.R., Lam, Y.K., and Uhlig, H.H. (2024). Short-chain fatty acids: linking diet,
1578 the microbiome and immunity. *Nat. Rev. Immunol.* 24, 577–595.
- 1579 42. Silva, Y.P., Bernardi, A., and Frozza, R.L. (2020). The role of short-chain fatty acids
1580 from gut Microbiota in gut-brain communication. *Front. Endocrinol.* 11, 25.
- 1581 43. van der Hee, B., and Wells, J.M. (2021). Microbial regulation of host physiology by
1582 short-chain fatty acids. *Trends Microbiol.* 29, 700–712.
- 1583 44. Verma, A., Bhagchandani, T., Rai, A., Nikita, Sardarni, U.K., Bhavesh, N.S., Gulati,
1584 S., Malik, R., and Tandon, R. (2024). Short-chain fatty acid (SCFA) as a connecting
1585 link between Microbiota and gut-lung axis-A potential therapeutic intervention to
1586 improve lung health. *ACS Omega* 9, 14648–14671.
- 1587 45. González-Hernández, L.A., Ruiz-Briseño, M.D.R., Sánchez-Reyes, K., Alvarez-
1588 Zavala, M., Vega-Magaña, N., López-Iñiguez, A., Díaz-Ramos, J.A., Martínez-
1589 Ayala, P., Soria-Rodriguez, R.A., Ramos-Solano, M., et al. (2019). Alterations in
1590 bacterial communities, SCFA and biomarkers in an elderly HIV-positive and HIV-
1591 negative population in western Mexico. *BMC Infect. Dis.* 19, 234.
- 1592 46. Enriquez, A.B., Ten Caten, F., Ghneim, K., Sekaly, R.-P., and Sharma, A.A. (2023).
1593 Regulation of immune homeostasis, inflammation, and HIV persistence by the
1594 microbiome, short-chain fatty acids, and bile acids. *Annu. Rev. Virol.* 10, 397–422.
- 1595 47. Hollenbaugh, J.A., Munger, J., and Kim, B. (2011). Metabolite profiles of human
1596 immunodeficiency virus infected CD4+ T cells and macrophages using LC-MS/MS
1597 analysis. *Virology* 415, 153–159.
- 1598 48. Mahalingam, S.S., Jayaraman, S., Bhaskaran, N., Schneider, E., Faddoul, F., Paes
1599 da Silva, A., Lederman, M.M., Asaad, R., Adkins-Travis, K., Shriver, L.P., et al.
1600 (2023). Polyamine metabolism impacts T cell dysfunction in the oral mucosa of
1601 people living with HIV. *Nat. Commun.* 14, 399.
- 1602 49. Moon, J.-Y., Zolnik, C.P., Wang, Z., Qiu, Y., Usyk, M., Wang, T., Kizer, J.R.,
1603 Landay, A.L., Kurland, I.J., Anastos, K., et al. (2018). Gut microbiota and plasma
1604 metabolites associated with diabetes in women with, or at high risk for, HIV
1605 infection. *EBioMedicine* 37, 392–400.
- 1606 50. Li, X., Wu, T., Jiang, Y., Zhang, Z., Han, X., Geng, W., Ding, H., Kang, J., Wang,
1607 Q., and Shang, H. (2018). Plasma metabolic changes in Chinese HIV-infected
1608 patients receiving lopinavir/ritonavir based treatment: Implications for HIV precision
1609 therapy. *Cytokine* 110, 204–212.
- 1610 51. Ding, Y., Lin, H., Chen, X., Zhu, B., Xu, X., Xu, X., Shen, W., Gao, M., and He, N.
1611 (2021). Comprehensive metabolomics profiling reveals common metabolic
1612 alterations underlying the four major non-communicable diseases in treated HIV
1613 infection. *EBioMedicine* 71, 103548.
- 1614 52. Cassol, E., Misra, V., Holman, A., Kamat, A., Morgello, S., and Gabuzda, D. (2013).
1615 Plasma metabolomics identifies lipid abnormalities linked to markers of

- 1616 inflammation, microbial translocation, and hepatic function in HIV patients receiving
1617 protease inhibitors. *BMC Infect. Dis.* *13*, 203.
- 1618 53. Babu, H., Sperk, M., Ambikan, A.T., Rachel, G., Viswanathan, V.K., Tripathy, S.P.,
1619 Nowak, P., Hanna, L.E., and Neogi, U. (2019). Plasma metabolic signature and
1620 abnormalities in HIV-infected individuals on long-term successful antiretroviral
1621 therapy. *Metabolites* *9*, 210.
- 1622 54. Taylor, B.C., Weldon, K.C., Ellis, R.J., Franklin, D., Groth, T., Gentry, E.C., Tripathi,
1623 A., McDonald, D., Humphrey, G., Bryant, M., et al. (2020). Depression in individuals
1624 coinfecting with HIV and HCV is associated with systematic differences in the gut
1625 microbiome and metabolome. *mSystems* *5*.
1626 <https://doi.org/10.1128/mSystems.00465-20>.
- 1627 55. Pedersen, M., Nielsen, C.M., and Permin, H. (1991). HIV antigen-induced release
1628 of histamine from basophils from HIV infected patients. Mechanism and relation to
1629 disease progression and immunodeficiency. *Allergy* *46*, 206–212.
- 1630 56. Armstrong, A.J.S., Shaffer, M., Nusbacher, N.M., Griesmer, C., Fiorillo, S.,
1631 Schneider, J.M., Preston Neff, C., Li, S.X., Fontenot, A.P., Campbell, T., et al.
1632 (2018). An exploration of Prevotella-rich microbiomes in HIV and men who have
1633 sex with men. *Microbiome* *6*, 198.
- 1634 57. Fusco, W., Lorenzo, M.B., Cintoni, M., Porcari, S., Rinninella, E., Kaitsas, F., Lener,
1635 E., Mele, M.C., Gasbarrini, A., Collado, M.C., et al. (2023). Short-chain fatty-acid-
1636 producing bacteria: Key components of the human gut Microbiota. *Nutrients* *15*.
1637 <https://doi.org/10.3390/nu15092211>.
- 1638 58. Hövelmann, Y., Steinert, K., Hübner, F., and Humpf, H.-U. (2020). Identification of a
1639 novel N-caprylhistamine- β -glucoside from tomato fruits and LC-MS/MS-based food
1640 screening for imidazole alkaloids. *Food Chem.* *312*, 126068.
- 1641 59. Hövelmann, Y., Hahn, M., Hübner, F., and Humpf, H.-U. (2019). Detection of novel
1642 cytotoxic imidazole alkaloids in tomato products by LC-MS/MS. *J. Agric. Food*
1643 *Chem.* *67*, 3670–3678.
- 1644 60. Takao, K., Noguchi, K., Hashimoto, Y., Shirahata, A., and Sugita, Y. (2015).
1645 Synthesis and evaluation of fatty acid amides on the N-oleoylethanolamide-like
1646 activation of peroxisome proliferator activated receptor α . *Chem. Pharm. Bull.* *63*,
1647 278–285.
- 1648 61. Huang, W., Rha, G.B., Han, M.-J., Eum, S.Y., András, I.E., Zhong, Y., Hennig, B.,
1649 and Toborek, M. (2008). PPAR α and PPAR γ effectively protect against
1650 HIV-induced inflammatory responses in brain endothelial cells. *J. Neurochem.* *107*,
1651 497–509.
- 1652 62. Crakes, K.R., Santos Rocha, C., Grishina, I., Hirao, L.A., Napoli, E., Gaulke, C.A.,
1653 Fenton, A., Datta, S., Arredondo, J., Marco, M.L., et al. (2019). PPAR α -targeted
1654 mitochondrial bioenergetics mediate repair of intestinal barriers at the host-microbe
1655 intersection during SIV infection. *Proc. Natl. Acad. Sci. U. S. A.* *116*, 24819–24829.






- 1656 63. Roan, N.R., and Greene, W.C. (2007). A seminal finding for understanding HIV
1657 transmission. *Cell* *131*, 1044–1046.
- 1658 64. Herbert, C., Luies, L., Loots, D.T., and Williams, A.A. (2023). The metabolic
1659 consequences of HIV/TB co-infection. *BMC Infect. Dis.* *23*, 536.
- 1660 65. Zhang, Y., Xie, Z., Zhou, J., Li, Y., Ning, C., Su, Q., Ye, L., Ai, S., Lai, J., Pan, P., et
1661 al. (2022). The altered metabolites contributed by dysbiosis of gut microbiota are
1662 associated with microbial translocation and immune activation during HIV infection.
1663 *Front. Immunol.* *13*, 1020822.
- 1664 66. Wu, R., Chen, X., Kang, S., Wang, T., Gnanaprakasam, J.R., Yao, Y., Liu, L., Fan,
1665 G., Burns, M.R., and Wang, R. (2020). De novo synthesis and salvage pathway
1666 coordinately regulate polyamine homeostasis and determine T cell proliferation and
1667 function. *Sci. Adv.* *6*, eabc4275.
- 1668 67. Puleston, D.J., Baixauli, F., Sanin, D.E., Edwards-Hicks, J., Villa, M., Kabat, A.M.,
1669 Kamiński, M.M., Stanckzak, M., Weiss, H.J., Grzes, K.M., et al. (2021). Polyamine
1670 metabolism is a central determinant of helper T cell lineage fidelity. *Cell* *184*, 4186–
1671 4202.e20.
- 1672 68. Lee, S.H., Kim, S.O., Lee, H.D., and Chung, B.C. (1998). Estrogens and
1673 polyamines in breast cancer: their profiles and values in disease staging. *Cancer*
1674 *Lett.* *133*, 47–56.
- 1675 69. Paik, M.-J., Lee, S., Cho, K.-H., and Kim, K.-R. (2006). Urinary polyamines and N-
1676 acetylated polyamines in four patients with Alzheimer's disease as their N-
1677 ethoxycarbonyl-N-pentafluoropropionyl derivatives by gas chromatography-mass
1678 spectrometry in selected ion monitoring mode. *Anal. Chim. Acta* *576*, 55–60.
- 1679 70. Kovács, T., Mikó, E., Vida, A., Sebő, É., Toth, J., Csonka, T., Boratkó, A., Ujlaki,
1680 G., Lente, G., Kovács, P., et al. (2019). Cadaverine, a metabolite of the
1681 microbiome, reduces breast cancer aggressiveness through trace amino acid
1682 receptors. *Sci. Rep.* *9*, 1300.
- 1683 71. Salzman, S.K., and Stepita-Klauco, M. (1981). Inhibition of evoked dopamine
1684 release by monopropionylcadaverine in vitro. *Pharmacol. Biochem. Behav.* *15*,
1685 119–123.
- 1686 72. Murray, K.E., Shaw, K.J., Adams, R.F., and Conway, P.L. (1993). Presence of N-
1687 acyl and acetoxy derivatives of putrescine and cadaverine in the human gut. *Gut*
1688 *34*, 489–493.
- 1689 73. Salzman, S.K., and Stepita-Klauco, M. (1981). Cadaverine in the rat brain: regional
1690 distribution and acylation of [¹⁴C]cadaverine in vivo and uptake in vitro. *J.*
1691 *Neurochem.* *37*, 1308–1315.
- 1692 74. Mayers, J.R., Varon, J., Zhou, R.R., Daniel-Ivad, M., Beaulieu, C., Bhosle, A.,
1693 Glasser, N.R., Lichtenauer, F.M., Ng, J., Vera, M.P., et al. (2024). A metabolomics
1694 pipeline highlights microbial metabolism in bloodstream infections. *Cell* *187*, 4095–
1695 4112.e21.





- 1696 75. Dudkina, N., Park, H.B., Song, D., Jain, A., Khan, S.A., Flavell, R.A., Johnson,
1697 C.H., Palm, N.W., and Crawford, J.M. (2024). Human AKR1C3 binds agonists of
1698 GPR84 and participates in an expanded polyamine pathway. *Cell Chem. Biol.*
1699 <https://doi.org/10.1016/j.chembiol.2024.07.011>.
- 1700 76. Elmassry, M.M., Sugihara, K., Chankhamjon, P., Camacho, F.R., Wang, S.,
1701 Sugimoto, Y., Chatterjee, S., Chen, L.A., Kamada, N., and Donia, M.S. (2024). A
1702 meta-analysis of the gut microbiome in inflammatory bowel disease patients
1703 identifies disease-associated small molecules. *bioRxiv.org*.
1704 <https://doi.org/10.1101/2024.02.07.579278>.
- 1705 77. Merali, S., Barrero, C.A., Sacktor, N.C., Haughey, N.J., Datta, P.K., Langford, D.,
1706 and Khalili, K. (2014). Polyamines: Predictive biomarker for HIV-associated
1707 neurocognitive disorders. *J. AIDS Clin. Res.* 5, 1000312.
- 1708 78. Lyons, D.E., Beery, J.T., Lyons, S.A., and Taylor, S.L. (1983). Cadaverine and
1709 aminoguanidine potentiate the uptake of histamine in vitro in perfused intestinal
1710 segments of rats. *Toxicol. Appl. Pharmacol.* 70, 445–458.
- 1711 79. Sánchez-Pérez, S., Comas-Basté, O., Costa-Catala, J., Iduriaga-Platero, I.,
1712 Veciana-Nogués, M.T., Vidal-Carou, M.C., and Latorre-Moratalla, M.L. (2022). The
1713 rate of histamine degradation by diamine oxidase is compromised by other biogenic
1714 amines. *Front. Nutr.* 9, 897028.
- 1715 80. Hui, J.Y., and Taylor, S.L. (1985). Inhibition of in vivo histamine metabolism in rats
1716 by foodborne and pharmacologic inhibitors of diamine oxidase, histamine N-
1717 methyltransferase, and monoamine oxidase. *Toxicol. Appl. Pharmacol.* 81, 241–
1718 249.
- 1719 81. Schmid, R., Petras, D., Nothias, L.-F., Wang, M., Aron, A.T., Jagels, A., Tsugawa,
1720 H., Rainer, J., Garcia-Aloy, M., Dührkop, K., et al. (2021). Ion identity molecular
1721 networking for mass spectrometry-based metabolomics in the GNPS environment.
1722 *Nat. Commun.* 12, 3832.
- 1723 82. Bittremieux, W., Chen, C., Dorrestein, P.C., Schymanski, E.L., Schulze, T.,
1724 Neumann, S., Meier, R., Rogers, S., and Wang, M. (2020). Universal MS/MS
1725 Visualization and Retrieval with the Metabolomics Spectrum Resolver Web Service.
1726 *bioRxiv*, 2020.05.09.086066. <https://doi.org/10.1101/2020.05.09.086066>.
- 1727 83. Nothias, L.-F., Petras, D., Schmid, R., Dührkop, K., Rainer, J., Sarvepalli, A.,
1728 Protsyuk, I., Ernst, M., Tsugawa, H., Fleischauer, M., et al. (2020). Feature-based
1729 molecular networking in the GNPS analysis environment. *Nat. Methods* 17, 905–
1730 908.
- 1731 84. Bittremieux, W., Avalon, N.E., Thomas, S.P., Kakhkhorov, S.A., Aksenov, A.A.,
1732 Gomes, P.W.P., Aceves, C.M., Caraballo-Rodríguez, A.M., Gauglitz, J.M., Gerwick,
1733 W.H., et al. (2023). Open access repository-scale propagated nearest neighbor
1734 suspect spectral library for untargeted metabolomics. *Nat. Commun.* 14, 8488.
- 1735 85. Frank, A.M., Monroe, M.E., Shah, A.R., Carver, J.J., Bandeira, N., Moore, R.J.,


- 1736 Anderson, G.A., Smith, R.D., and Pevzner, P.A. (2011). Spectral archives:
1737 extending spectral libraries to analyze both identified and unidentified spectra. *Nat.*
1738 *Methods* 8, 587–591.
- 1739 86. Gauglitz, J.M., West, K.A., Bittremieux, W., Williams, C.L., Weldon, K.C.,
1740 Panitchpakdi, M., Di Ottavio, F., Aceves, C.M., Brown, E., Sikora, N.C., et al.
1741 (2022). Enhancing untargeted metabolomics using metadata-based source
1742 annotation. *Nat. Biotechnol.* 40, 1774–1779.
- 1743 87. Conway, J.R., Lex, A., and Gehlenborg, N. (2017). UpSetR: an R package for the
1744 visualization of intersecting sets and their properties. *Bioinformatics* 33, 2938–
1745 2940.
- 1746 88. Schmid, R., Heuckeroth, S., Korf, A., Smirnov, A., Myers, O., Dyrland, T.S.,
1747 Bushuiev, R., Murray, K.J., Hoffmann, N., Lu, M., et al. (2023). Integrative analysis
1748 of multimodal mass spectrometry data in MZmine 3. *Nat. Biotechnol.*
1749 <https://doi.org/10.1038/s41587-023-01690-2>.
- 1750 89. Kessner, D., Chambers, M., Burke, R., Agus, D., and Mallick, P. (2008).
1751 ProteoWizard: open source software for rapid proteomics tools development.
1752 *Bioinformatics* 24, 2534–2536.
- 1753 90. Heaton, R.K., Franklin, D.R., Ellis, R.J., McCutchan, J.A., Letendre, S.L., Leblanc,
1754 S., Corkran, S.H., Duarte, N.A., Clifford, D.B., Woods, S.P., et al. (2011). HIV-
1755 associated neurocognitive disorders before and during the era of combination
1756 antiretroviral therapy: differences in rates, nature, and predictors. *J. Neurovirol.* 17,
1757 3–16.
- 1758 91. Woods, S.P., Rippeth, J.D., Frol, A.B., Levy, J.K., Ryan, E., Soukup, V.M., Hinkin,
1759 C.H., Lazzaretto, D., Cherner, M., Marcotte, T.D., et al. (2004). Interrater reliability
1760 of clinical ratings and neurocognitive diagnoses in HIV. *J. Clin. Exp. Neuropsychol.*
1761 26, 759–778.
- 1762 92. Antinori, A., Arendt, G., Becker, J.T., Brew, B.J., Byrd, D.A., Cherner, M., Clifford,
1763 D.B., Cinque, P., Epstein, L.G., Goodkin, K., et al. (2007). Updated research
1764 nosology for HIV-associated neurocognitive disorders. *Neurology* 69, 1789–1799.
- 1765 93. Brennan, C., Belda-Ferre, P., Zuffa, S., Charron-Lamoureux, V., Mohanty, I.,
1766 Ackermann, G., Allaband, C., Ambre, M., Boyer, T., Bryant, M., et al. (2024).
1767 Clearing the plate: a strategic approach to mitigate well-to-well contamination in
1768 large-scale microbiome studies. *mSystems*, e0098524.
- 1769 94. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin,
1770 N., Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for
1771 integrated models of biomolecular interaction networks. *Genome Res.* 13, 2498–
1772 2504.
- 1773 95. Sanders, J.G., Nurk, S., Salido, R.A., Minich, J., Xu, Z.Z., Zhu, Q., Martino, C.,
1774 Fedarko, M., Arthur, T.D., Chen, F., et al. (2019). Optimizing sequencing protocols
1775 for leaderboard metagenomics by combining long and short reads. *Genome Biol.*

- 1776 20, 226.
- 1777 96. Brennan, C., Salido, R.A., Belda-Ferre, P., Bryant, M., Cowart, C., Tiu, M.D.,
1778 González, A., McDonald, D., Tribelhorn, C., Zarrinpar, A., et al. (2023). Maximizing
1779 the potential of high-throughput next-generation sequencing through precise
1780 normalization based on read count distribution. *mSystems* 8, e0000623.
- 1781 97. Armstrong, G., Martino, C., Morris, J., Khaleghi, B., Kang, J., DeReus, J., Zhu, Q.,
1782 Roush, D., McDonald, D., Gonzalez, A., et al. (2022). Swapping metagenomics
1783 preprocessing pipeline components offers speed and sensitivity increases.
1784 *mSystems* 7, e0137821.
- 1785 98. Zhu, Q., Mai, U., Pfeiffer, W., Janssen, S., Asnicar, F., Sanders, J.G., Belda-Ferre,
1786 P., Al-Ghalith, G.A., Kopylova, E., McDonald, D., et al. (2019). Phylogenomics of
1787 10,575 genomes reveals evolutionary proximity between domains Bacteria and
1788 Archaea. *Nat. Commun.* 10, 5477.
- 1789 99. Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie
1790 2. *Nat. Methods* 9, 357–359.
- 1791 100. Zhu, Q., Huang, S., Gonzalez, A., McGrath, I., McDonald, D., Haiminen, N.,
1792 Armstrong, G., Vázquez-Baeza, Y., Yu, J., Kuczynski, J., et al. (2022). Phylogeny-
1793 aware analysis of metagenome community ecology based on matched reference
1794 genomes while bypassing taxonomy. *mSystems* 7, e0016722.
- 1795 101. Sepich-Poore, G.D., McDonald, D., Kopylova, E., Guccione, C., Zhu, Q., Austin, G.,
1796 Carpenter, C., Fraraccio, S., Wandro, S., Kosciolk, T., et al. (2024). Robustness of
1797 cancer microbiome signals over a broad range of methodological variation.
1798 *Oncogene* 43, 1127–1148.
- 1799 102. Chen, S., Zhou, Y., Chen, Y., and Gu, J. (2018). fastp: an ultra-fast all-in-one
1800 FASTQ preprocessor. *Bioinformatics* 34, i884–i890.
- 1801 103. Liao, W.-W., Asri, M., Ebler, J., Doerr, D., Haukness, M., Hickey, G., Lu, S., Lucas,
1802 J.K., Monlong, J., Abel, H.J., et al. (2023). A draft human pangenome reference.
1803 *Nature* 617, 312–324.
- 1804 104. Rhie, A., Nurk, S., Cechova, M., Hoyt, S.J., Taylor, D.J., Altemose, N., Hook, P.W.,
1805 Koren, S., Rautiainen, M., Alexandrov, I.A., et al. (2023). The complete sequence
1806 of a human Y chromosome. *Nature* 621, 344–354.
- 1807 105. Schneider, V.A., Graves-Lindsay, T., Howe, K., Bouk, N., Chen, H.-C., Kitts, P.A.,
1808 Murphy, T.D., Pruitt, K.D., Thibaud-Nissen, F., Albracht, D., et al. (2017).
1809 Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the
1810 enduring quality of the reference assembly. *Genome Res.* 27, 849–864.
- 1811 106. Li, H. (2021). New strategies to improve minimap2 alignment accuracy.
1812 *Bioinformatics* 37, 4572–4574.
- 1813 107. Danecek, P., Bonfield, J.K., Liddle, J., Marshall, J., Ohan, V., Pollard, M.O.,
1814 Whitwham, A., Keane, T., McCarthy, S.A., Davies, R.M., et al. (2021). Twelve years
1815 of SAMtools and BCFtools. *Gigascience* 10.

- 1816 <https://doi.org/10.1093/gigascience/giab008>.
- 1817 108. Edwards, J.A., and Edwards, R.A. (2019). Fastq-pair: efficient synchronization of
1818 paired-end fastq files. <https://doi.org/10.1101/552885>.
- 1819 109. Tange, O. (2018). Gnu Parallel 2018 (Zenodo).
- 1820 110. Köster, J. (2016). Rust-Bio: a fast and safe bioinformatics library. *Bioinformatics* 32,
1821 444–446.
- 1822 111. Gonzalez, A., Navas-Molina, J.A., Kosciolk, T., McDonald, D., Vázquez-Baeza, Y.,
1823 Ackermann, G., DeReus, J., Janssen, S., Swafford, A.D., Orchanian, S.B., et al.
1824 (2018). Qiita: rapid, web-enabled microbiome meta-analysis. *Nat. Methods* 15,
1825 796–798.
- 1826 112. Hakim, D., Wandro, S., Zengler, K., Zaramela, L.S., Nowinski, B., Swafford, A.,
1827 Zhu, Q., Song, S.J., Gonzalez, A., McDonald, D., et al. (2022). Zebra: Static and
1828 dynamic genome cover thresholds with overlapping references. *mSystems* 7,
1829 e0075822.
- 1830 113. Bolyen, E., Rideout, J.R., Dillon, M.R., Bokulich, N.A., Abnet, C.C., Al-Ghalith, G.A.,
1831 Alexander, H., Alm, E.J., Arumugam, M., Asnicar, F., et al. (2019). Reproducible,
1832 interactive, scalable and extensible microbiome data science using QIIME 2. *Nat.*
1833 *Biotechnol.* 37, 852–857.
- 1834 114. Vázquez-Baeza, Y., Pirrung, M., Gonzalez, A., and Knight, R. (2013). EMPeror: a
1835 tool for visualizing high-throughput microbial community data. Preprint,
1836 <https://doi.org/10.1186/2047-217x-2-16> <https://doi.org/10.1186/2047-217x-2-16>.
- 1837 115. ICH (2005). International Conference on Harmonization (ICH) of Technical
1838 Requirements for Registration of Pharmaceuticals for Human Use. Preprint at Topic
1839 Q9: Quality Risk Management Geneva.
- 1840 116. Adams, K.J., Pratt, B., Bose, N., Dubois, L.G., St John-Williams, L., Perrott, K.M.,
1841 Ky, K., Kapahi, P., Sharma, V., MacCoss, M.J., et al. (2020). Skyline for Small
1842 Molecules: A Unifying Software Package for Quantitative Metabolomics. *J.*
1843 *Proteome Res.* 19, 1447–1458.
- 1844 117. Melnik, A.V., da Silva, R.R., Hyde, E.R., Aksenov, A.A., Vargas, F., Bouslimani, A.,
1845 Protsyuk, I., Jarmusch, A.K., Tripathi, A., Alexandrov, T., et al. (2017). Coupling
1846 targeted and untargeted mass spectrometry for metabolome-microbiome-wide
1847 association studies of human fecal samples. *Anal. Chem.* 89, 7549–7559.
- 1848
- 1849





A**B**